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Mechanisms of Stem Cell Regulation in Medulloblastoma 
 
Abstract 
Medulloblastoma, the most common pediatric malignant brain tumor, is comprised of a 
heterogeneous group of tumors with distinct molecular subtypes and clinical outcomes. In 
particular, tumors with a cancer stem cell (CSC) population have been observed to be more 
resistant to conventional therapies, necessitating the elucidation of pathways important in this 
population. Work in our lab has shown that neurosphere culture-enriched cells from 
Ptch1
LacZ/+
;Trp53
-/-  
mouse medulloblastomas exhibit properties of self-renewal, expression of 
neural stem cell (NSC) markers and potent tumor-initiation. The pathway dependencies and 
mechanisms of self-renewal in these medulloblastoma neurospheres (MBNS) have not yet been 
characterized. 
 Reprogramming and dedifferentiation of tumor cells have been proposed as a mechanism 
for the establishment and maintenance of CSC. To test this, we asked if the endogenous genetic 
program of the Ptch1
LacZ/+
;Trp53
-/-
 MBNS was sufficient for the reprogramming of tumor cells 
into a pluripotent-like state in vitro. We observed that MBNS, unlike normal cerebellar stem 
cells (CbSC), were able to form embryonic stem (ES) cell-like colonies upon growth in ES 
culture conditions. Klf4, a reprogramming factor, was identified to be functionally important in 
maintaining both MBNS plasticity upon transfer to ES culture conditions and clonal self-renewal 
as neurospheres. Further, Klf4 expression compensated for Stat3 inhibition in a Stat3-
 iv 
independent manner for the maintenance of survival gene expression, thus identifying a novel 
compensatory transcriptional mechanism enhancing the survival of CSC.  
 We further characterized Sox2, a NSC marker highly expressed in the MBNS, as a 
definitive marker for the isolation of self-renewing CbSC from postnatal day 7 wild-type (WT) 
animals. Moreover, Sox2 expression was maintained in the cerebella of 3-week-old 
Ptch1
LacZ/+
;Trp53
-/-
 animals and the prospective isolation of the Sox2-positive cells enriched for 
the aberrantly persisting, self-renewing cells, which are absent in by 3 weeks in WT animals. 
Thus, we have validated an endogenous Sox2-GFP reporter system that allows for the 
prospective isolation of the aberrant tissue stem cells from Ptch1
LacZ/+
;Trp53
-/-
 animals, which 
will be valuable for furthering our understanding of stem cell regulation during medulloblastoma 
tumorigenesis.  
 v 
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Chapter 1 : Introduction 
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Medulloblastoma Overview 
 
Medulloblastoma, a primitive neuroectodermal tumor arising in the cerebellum, is the 
most common malignant childhood brain cancer and accounts for about 20% of pediatric brain 
tumors (Ellison et al., 2003). Peak incidences occur in children from ages 3-4 and ages 8-9 and 
about 10% of cases occur in infants (Crawford et al., 2007). While overall survival rates of 
medulloblastoma patients are about 80%, aggressive and non-specific conventional treatment 
strategies usually result in long-term cognitive deficits and neuroendocrinal abnormalities 
(Ellison et al., 2003). Furthermore, aggressive tumor subtypes with a disseminated phenotype are 
associated with a higher frequency of relapse and have poor prognoses (Zeltzer et al., 1999; 
Northcott et al., 2011b). Such relapse mechanisms have been attributed to a subset of cancer 
stem cells (CSC) in the bulk tumor (Clarke et al., 2006), which have, in fact, been identified in 
human medulloblastomas (Singh et al., 2004). In the recent decade, immense advances have 
been made in the elucidation of the molecular underpinnings of medulloblastoma tumorigenesis 
(Taylor et al., 2012), while the understanding of the tumor-initiating cells remains relatively 
sparse. As such, the identification of molecular pathways involved in CSC homeostasis could 
have potential ramifications for better risk-stratification and allow for the development of 
targeted therapeutic strategies to increase efficacy and reduce long-term sequelae in patients. 
 
Clinical features of human medulloblastoma 
 
The World Health Organization (WHO) classifies all medulloblastomas as malignant and 
invasive grade IV tumors. Based on the WHO classification, there are five histological variants 
of human medulloblastoma: classic, desmoplastic/nodular, extensive nodularity, large cell, and 
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anaplastic (Louis et al., 2007). Classic medulloblastomas, which make up about ~70% of all 
cases (Ellison et al., 2011) are characterized by sheets of undifferentiated cells with high nuclei 
to cytoplasm ratios. Desmoplastic/nodular and extensive nodularity tumors are closely related 
variants, both characterized by nodules (pale islands) of tumor cells undergoing neuronal 
differentiation, interspersed with stroma composed of reticulin (type III collagen) fibers. The 
internodular, reticulin regions are reduced in the extensive nodularity tumors compared to the 
desmoplastic tumors. The last two variants, the anaplastic and large cell medulloblastomas, 
which are cytologically similar, are marked with high mitotic activity and atypical nuclear 
pleomorphisms and are the most aggressive and treatment-resistant tumors. 
Current risk stratification of patients is based on age, extent of surgical resection, and 
metastatic status. Standard risk patients include those greater than 3 years of age, with complete 
or near complete surgical resection of the tumor (<1.5cm
2
 residual tumor) and absence of 
leptomeningeal dissemination; all other patients are classified as high risk (Zeltzer et al., 1999). 
Long-term survival rates of standard risk patients are 60-80%, but surviving patients are often 
subject to a variety of long-term sequelae such as cognitive decline and neuroendocrinal defects, 
due to the non-specific and aggressive nature of standard treatment modalities, which entail post-
operative radiation and chemotherapy (Dennis et al., 1996; Crawford et al., 2007). While efforts 
have been made to reduce the doses of irradiation, this has been associated with a subsequent 
increase in the risk of relapse (Thomas et al., 2000). Furthermore, in the most recently published 
study of long-term effects of patients treated for standard-risk medulloblastoma, lower doses of 
radiospinal therapy than the standard dose (24Gy vs. 36Gy), nevertheless resulted in progressive 
decline in intellectual and academic scores (Ris et al., 2013). Currently, young age at diagnosis is 
consistently the most important risk factor in determining if neurocognitive defects will follow a 
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standard treatment regime (Ris et al., 2013). Given the non-specific modalities of the current 
therapies and their significant developmental impact, especially in young patients, a better 
understanding of specific molecular pathways involved in medulloblastoma tumorigenesis is 
crucial for the development of targeted therapies and improved risk stratification. 
 
Cerebellar development 
 
The cerebellum has been referred to as the “coordination center” of the brain, playing a 
role in balance and the fine tuning of motor movements (Wang and Zoghbi, 2001). In addition to 
the well-established role of the cerebellum in motor control, it has also been implicated in higher 
cognitive functions including spatial memory, speech and sensory motor learning (Hatten and 
Roussel, 2011; Marino, 2005). In humans and mice, the formation of the mature cerebellum is a 
protracted developmental process that continues postnatally for months after birth in humans and 
weeks in mice. Abnormalities during cerebellar development lead to developmental defects 
affecting balance and coordination such as Chiari malformations and Dandy-Walker syndrome 
or may lead to malignant transformation, resulting in medulloblastoma (Wang et al., 2003). 
Therefore, an understanding of the genetic pathways regulating cerebellar development and the 
cell types present during the process is crucial in studying the mechanisms of tumorigenesis. 
During mouse embryogenesis, the cerebellum arises from two embryonic germinal zones, 
the ventricular zone (VZ) and the rhombic lip (RL) (Figure 1-1a). In mice, by embryonic day 14 
(E14), early progenitors in the ventricular zone, marked by Ptf1 expression (Hoshino et al., 
2005), cease proliferation and begin to differentiate to give rise to calbindin-positive Purkinje 
neurons. Between E14-E17, the postmitotic Purkinje neurons subsequently migrate radially 
along glial fibers to establish the cerebellar field (Hatten and Heintz, 1995), by secreting Sonic 
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Hedgehog (SHH), a factor important for the proliferation and differentiation of granule neurons 
(Wechsler-Reya and Scott, 1999). In addition to Purkinje neuron fate determination, the Ptf1-
expressing cells from the ventricular zone are also thought to give rise to other GABAergic 
neurons in the cerebella including the Golgi, basket, and stellate cells (Hoshino et al., 2005). 
 The granule neurons of the cerebella are derived from another germinal epithelium, 
known as the rhombic lip (Figure 1-1a), located in between the neural tube and the fourth 
ventricle. Around E13, Math1-positive cells migrate out of the rhombic lip and coat the surface 
of the developing cerebellar field to form the external granule layer (EGL) (Hatten and Heintz, 
1995; Ben-Arie et al., 1997), which by postnatal day 0 (P0) is composed of a single layer of 
undifferentiated cells (Figure 1-1b). Beginning around postnatal day 7 (P7), the majority of the 
Math1-positive cells in the EGL form a zone of proliferating granule cell progenitors (GCP) that 
are driven by SHH secreted by the Purkinje neurons (Figure 1-1b, c) (Wechsler-Reya and Scott, 
1999). This large clonal expansion continues until P15, after which the post-mitotic granule cells 
exit the cell cycle, downregulate Math1 expression and move inwards from the EGL along the 
radial fibers of Bergmann glia cells to form the internal granule layer (IGL) (Hatten and Heintz, 
1995; Hatten et al., 1997). In normal development, cerebellar development is largely complete 
by P21, when the EGL diminishes as the mature granule neurons migrate into the IGL, leaving 
the trailing processes in the molecular layer (Wechsler-Reya and Scott, 2001). Dysregulated 
granule cell proliferation during cerebellar development results in the formation of an 
abnormally thickened EGL, containing aberrantly proliferative “rests”, which may subsequently 
lead to tumorigenesis upon acquisition of additional mutations (Kim et al., 2003). 
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Figure 1-1 Overview of mouse cerebellar development through embryonic and postnatal development  
(a) Around E13, Math1-expressing cells from the rhombic lip migrate rostrally over the surface of the cerebellum to 
form the external granule layer (EGL). Purkinje cells are derived from the Ptf1-expressing progenitors from the 
ventricular zone around E14 and migrate radially. (b) Histology of sagittal sections of mouse cerebella 
corresponding to the different stages during cerebellar development: postnatal day 0 (P0), day 7 (P7), and adult. “P” 
denotes the Purkinje cell layer. Images are taken from Goldowitz and Hambre, 1998. (c) During the large clonal 
expansion and differentiation of the granule cell progenitors that occur during the first 2-3 weeks, postmitotic 
granule neurons migrate inwards to form the internal granule layer (IGL). They move past the Purkinje layer, which 
secrete SHH to regulate the proliferation of the progenitors, leaving behind processes in the molecular layer. Non-
neuronal cell types in the cerebellum include the Bergmann glia and oligodendrocytes (not shown). Figures are 
modified from Marino 2005 and Ruiz y Altaba et al., Nat Neuroscience 2002. 
a c 
b 
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Cerebellar Stem Cells  
 
 In addition to the granule neurons and Purkinje cells, which are the two major neuronal 
cells in the cerebellum, other cell types of the cerebellum include the Golgi, stellate and basket 
interneurons, the Bergmann glia (located at the border of Purkinje cell layer and the IGL) and 
oligodendrocytes (found in the white matter). Unlike the granule neurons and the Purkinje cells, 
whose cells of origin have been well characterized as the GCP of the EGL and the progenitor 
cells of the ventricular zone, respectively, the developmental origins of the interneurons, glial 
cells and the oligodendrocytes are much less clear.  
A multipotent cerebellar stem cell population with the ability to give rise to neurons, 
astrocytes, and oligodendrocytes in vitro and in vivo has, in fact, been isolated from the postnatal 
day 7 (P7) mouse cerebella (Lee et al., 2005). Prospective isolation of prominin 1 (Prom1)-
positive (also known as CD133) cells leads to the enrichment of these multipotent stem cells, 
which also exhibit self-renewal and high expression of NSC genes, SRY-box containing gene 2 
(Sox2) and nestin. This suggests that the different cell types of the cerebellum can arise from a 
common multipotent stem cell population, revealing another potential cell population for 
transformation during medulloblastoma tumorigenesis.  
 
Molecular classification of human medulloblastoma 
 
Early insights into the molecular basis of medulloblastomas were drawn from the 
identification of developmental pathways altered in hereditary tumor syndromes and the 
examination of their roles in cerebellar development (Wechsler-Reya and Scott, 2001). The role  
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of the SHH signaling pathway in medulloblastoma was first appreciated when individuals with 
Gorlin’s syndrome, which is characterized by heterozygous PTCH1 mutations, were observed to 
display a predisposition to develop medulloblastomas (Hahn et al, 1996). PTCH1, a receptor for 
SHH, functions as a negative regulator of SHH signaling by inhibiting smoothened (SMO), 
which activates the downstream GLI transcriptional factors. Upon SHH binding to the PTCH1 
receptor, SMO inhibition is relieved and the downstream GLI transcription factors are released 
from inhibitory complexes, which include the protein SUFU, to activate target gene expression 
(Figure 1-2) (Huse and Holland, 2010). Sporadic mutations in components of the SHH-PTCH1 
signaling pathway, including PTCH1, SUFU and SMO have been reported in 25% of 
medulloblastomas (Ellison et al., 2003). Similarly, the role of the WNT signaling pathway, 
known to be crucial during the embryonic development of the cerebellum and the midbrain 
(McMahon and Bradley, 1990; Thomas and Capecchi, 1990), was recognized by studying 
patients with Turcot’s syndrome. Turcot’s syndrome is characterized by the concomitant 
occurrence of multiple colorectal adenomas and a primary brain tumor, in particular 
medulloblastoma (Hamilton et al., 1995). These patients were identified to harbor germline 
mutations in the adenomatous polyposis coli (APC) gene, a tumor suppressor that regulates the 
activity of the transcriptional co-activator beta-catenin (CTNNB1), a key regulator of the WNT 
pathway (Figure 1-2). Mutations in the CTNNB1, APC, and AXIN, another component of the 
APC complex, have also been observed to occur in about 20% of sporadic medulloblastomas 
(Huse and Holland, 2010).  
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Figure 1-2 Developmental pathways implicated in medulloblastoma tumorigenesis 
Both germline and sporadic mutations in components of the SHH and WNT signaling pathways have been identified 
to occur in human medulloblastomas. Figure taken from Huse and Holland (2010).  
Four subtypes of human medulloblastoma 
 
While candidate gene approaches have been crucial to our early understanding of the 
molecular basis of medulloblastoma and the development of early mouse models, genome-wide 
expression analyses are critical for further identification of potential prognostic markers and 
elucidation of other pathways important in tumorigenesis. An early expression profiling study 
established that different tumor types and histological variants within the same tumor (ie. classic 
vs. desmoplastic medulloblastoma) are molecularly distinct and furthermore, gene expression 
signatures can serve as predictors of patient outcome (Pomeroy et al., 2002). Following this 
study, multiple transcriptional profiling studies have identified four to six subclasses of human 
medulloblastoma, highlighting medulloblastoma as a collection of tumors with distinct clinical 
features and outcomes, molecular underpinnings, and demographics and not a single-entity 
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disease (Kool et al., 2008; Northcott et al., 2011b; Cho et al., 2010). The current consensus as 
determined by the multiple groups that conducted the genome-wide analyses of the human 
tumors, identifies four distinct molecular subtypes; WNT, SHH, Group 3 (MYC), and Group 4 
tumors (Taylor et al., 2012) (Figure 1-3). Meta-analyses of the expression profiling data from 
seven independent studies show consistency in the tumor grouping, further validating the four 
consensus classes (Kool et al., 2012). 
The WNT and SHH subtypes show clear activation of the corresponding signaling 
pathways by target gene expression and make up the two groups that have the most favorable 
clinical outcomes, with survival rates of 80-90%. Group 3 and Group 4 have lower survival rates 
and while they have overlapping gene signatures, Group 3 tumors have an increased proportion 
of metastases and the worst prognosis (Northcott et al., 2011b). Given the molecular variation 
and differences in clinical outcomes, recent efforts have focused on developing and validating 
tumor subtype-specific mouse models of human medulloblastoma (Figure 1-3). As reviewed in 
the following sections, subtype-specific medulloblastoma models have also identified different 
putative subtype-specific tumor-initiating cells and cell of origins. 
 
WNT subtype: 
 
WNT tumors, which are characterized by the expression of genes present during 
activated WNT signaling (WIF1, DKK1, DKK2, etc.), constitute the subtype with the most 
favorable clinical outcome, with survival rates of over 95% in children and up to 100% in adults 
(Kool et al., 2012). The WNT tumors are a well-defined subclass characterized by distinct 
features, including mutations in beta-catenin (CTNNB1), loss of chromosome 6, and  
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Figure 1-3 The four molecular subtypes of human medulloblastoma  
Each subtype displays distinct clinical, genetic, and histological features. Subtype-specific mouse models have 
identified differences in the putative cell of origin. LCA=large cell anaplastic; SVZ=subventricular zone; 
GNP=granule neuron progenitors. Figure adapted from Northcott et al., 2012 and Lau et al. 2012. 
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immunopositivity for beta-catenin (Clifford et al., 2006). Metastases are rare in the WNT tumors 
and given the favorable clinical outcome of these tumors, efforts have begun to stratify patients 
with WNT tumors for consideration in reducing treatment intensities (Northcott et al., 2012). 
The WNT subtype was recently established in a mouse model with a stabilizing mutation 
of beta-catenin (Ctnnb1) (Gibson et al., 2010), which led to the abnormal accumulation of cells 
from the embryonic dorsal brainstem persisting into adulthood. However, tumors did not form 
without the inactivation of Trp53. Ctnnb1;Trp53 mutant tumors recapitulated the characteristics 
and gene expression of human WNT tumors. In this model, the cell of origin of the WNT 
subtype has been suggested to be the dorsal brainstem progenitor cell (Gibson et al., 2010).  
 
SHH subtype: 
SHH tumors exhibit activation of the SHH signaling pathway, a pathway critical for the 
proliferation and differentiation of the granule cell neurons, and are marked by expression of 
genes such as HHIP, ATOH1 (MATH1), and SFR1 as well as the SHH pathway-dependent 
transcription factors GLI1, GLI2, and GLI3 (Northcott et al., 2011b). Mutations associated with 
the SHH subtype include PTCH1 and SUFU, both negative regulators of SHH signaling. Overall 
survival rates are good, with 5 or 10 year survival rates of ~80%. However, further stratification 
of the group by age indicates that the overall survival of children and adults are worse (10 year 
survival of 51% and 34%, respectively) than infants, suggesting the need for further 
subcategorization. 
 The SHH subtype has the most well-established mouse models of medulloblastoma. 
Various models with activating mutations or overexpression of Smo (Hatton et al., 2008) or 
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inactivating mutations (Goodrich et al., 1997; Wetmore et al., 2001) or deletion (Yang et al., 
2008b; Schüller et al., 2008) of Ptch1 have been validated to recapitulate SHH human tumors. 
From the study of SHH subtype mouse models, it has been shown that both granule cell 
progenitors (GCP) and multipotent neural stem cells (NSC) can initiate medulloblastoma 
tumorigenesis following the inactivation of Ptch1. Cre-mediated deletion of Ptch1 in the granule 
lineage-committed Math1-expressing cells in E14.5 to postnatal day 10 (P10) mice result in 
tumor formation, indicating that both embryonic and postnatal GCP can function as tumor-
initiating cells (Yang et al., 2008b). Ptch1 deletion in GFAP-expressing multipotent NSC at 
E14.5 led to an expansion of the NSC in the embryonic cerebella, resulting in an abnormally 
thick EGL at birth and was soon followed by rapid tumor formation. However, no abnormalities 
were observed in astrocytes, oligodendrocytes and other non-granule neurons, suggesting that the 
oncogenic effects of the Ptch1 deletion are only evident in cells that have committed to the 
granule cell lineage (Yang et al., 2008b). Similarly, Schuller et al. (2008) showed that activation 
of Smo in Math1-expressing lineage-restricted progenitors, as well as early multipotent hGFAP
+
 
and Olig2
+
 progenitors led to GCP-activated medulloblastomas. No other tumor types were 
observed, despite the multipotency of the progenitors, consistent with the observation that 
acquisition of the granule cell lineage is critical for the development of SHH-induced tumors 
(Schüller et al., 2008).  
As a result of the well-characterized nature of the SHH pathway and its role in 
tumorigenesis, various mouse models have been used in preclinical studies to test inhibitors of 
the SHH pathway for potential therapeutics (Lau et al., 2012). In particular, SMO antagonists, 
such as Cyclopamine and HhAntag, have shown promise in Ptch1 models (Berman et al., 2002; 
Romer et al., 2004). Notably, a SMO antagonist (GDC-0449) resulted in rapid, albeit transient, 
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tumor regression in a patient with a SHH-activated tumor displaying widespread dissemination 
(Rudin et al., 2009). Nevertheless, further understanding of disease relapse and drug resistance 
mechanisms will be necessary for the development of effective treatments against SHH tumors. 
 
Group 3 
Group 3 human tumors, molecularly characterized by MYC overexpression or 
amplification, are more likely to exhibit metastases at time of diagnosis and have the poorest 
prognoses, with overall survival rates of 30-50% (Northcott et al., 2011b; Kool et al., 2012). 
Recently, two independent studies have validated the functional role of MYC overexpression in 
medulloblastoma tumorigenesis. Transformation of the postnatal cerebellar stem cells (CbSC) at 
P5-P7 with a stabilizing mutant of c-myc and dominant-negative Trp53 leads to highly 
aggressive tumor formation (Pei et al., 2012). While overexpression of c-myc and Trp53 in 
Math1-GFP GCP can also lead to tumor formation with lower penetrance and longer latency, the 
tumors that develop no longer express GFP, indicating that the expression of Math1, a key 
marker for granule lineage commitment is lost during tumorigenesis. Tumors arising from this 
model exhibit gene expression profiles that overlap with NSC, suggesting that the c-myc and 
Trp53-induced transformation may, in fact, be leading to the dedifferentiation to more primitive 
cell types during tumorigenesis (Pei et al., 2012; Kawauchi et al., 2012). While these recent 
studies have been significant in providing the first validated models for the Group 3 tumors, one 
must keep in mind that these models are generated by the ex vivo transformation of CbSC by 
retroviral overexpression. Establishment of an endogenous system for targeting CbSC will be 
important to further examine the potential role for CbSC in medulloblastoma tumorigenesis. 
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Group 4  
While Group 4 tumors are the most common subtype, it is by far the least characterized 
subtype of medulloblastoma (Kool et al., 2012). Group 4 tumors display overlapping gene 
expression profiles with Group 3 tumors, but are distinguished by the amplification of proto-
oncogene MYCN (Kool et al., 2012) and have better overall survival rates (~75%) (Northcott et 
al., 2012). In one model, the overexpression of Mycn in the postnatal day 0 cerebella led to the 
formation of SHH-independent tumors with LCA and classic histology, as typically observed in 
Group 4 tumors. Furthermore, these tumors, although infrequently, displayed leptomeningeal 
metastases and contain transplantable tumor-propagating cells (Swartling et al., 2010). However, 
this model still remains to be validated for recapitulation of the human Group 4 subtype tumors. 
 
Cancer Stem Cells 
 
Background 
 
A cancer stem cell is defined as a cell present in a tumor that possesses 1) the capability 
for self-renewal and 2) the ability to differentiate and give rise to the variety of heterogeneous 
progeny that make up the bulk of the tumor (Reya et al., 2001; Clarke et al., 2006). A self-
renewing cell must be able to generate a daughter cell that retains its ability for self-renewal and 
differentiation and occurs either by symmetrical (generating two stem cells) or asymmetrical cell 
division (generating one stem cell and one differentiated cell) (Clarke et al., 2006). The cancer 
stem cell hypothesis states that it is this rare population of cells with stem-like properties that 
drive the initiation and progression of the tumor and establish hierarchically organized, 
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differentiated tumor progeny. Therefore, akin to normal development, tumor heterogeneity is a 
result of the multipotent differentiation of the stem-like cell. By contrast, in the clonal, or 
stochastic model of tumorigenesis, any cell within the tumor that acquires the appropriate genetic 
and/or epigenetic alterations can gain the potential for tumor initiation (Shackleton et al., 2009; 
Dick, 2009). 
Cancer stem cells were first identified and characterized in human acute myeloid 
leukemia (AML). Drawing from the well-established markers of hematopoietic stem cells 
(HSC), Dick et al. (1994) observed that human AML cells with cell surface profiles 
(CD34
+
CD38
-
) typical of immature cells in the bone marrow were also able to regenerate 
leukemia and recapitulate the original tumor when serially transplanted into irradiated 
NOD/SCID mice. In contrast, the CD34
+
CD38
+
 or CD34
-
 cells failed to initiate leukemia 
(Lapidot et al., 1994; Bonnet and Dick, 1997). However, a CSC population is not necessarily 
derived from the transformation of the corresponding tissue stem cell. Increasing evidence has 
supported the notion that differentiated tissue progenitors, through oncogenic mutations, can 
dedifferentiate and acquire characteristics of CSC to initiate tumorigenesis (Passegué et al., 
2003). For example, the expression of the MLL-ENL and MLL-AF9 fusion oncogenes can bestow 
properties of self-renewal in committed progenitors in myeloid/lymphoid leukemia (Cozzio et 
al., 2003; Krivtsov et al., 2006). The extensive lineage maps and validated cell surface markers 
for each distinct cell lineage have made it feasible to study the role of each cell population during 
hematopoietic tumorigenesis. The challenge remains in solid tumors, as the surface markers of 
stem cells and their progeny or even the developmental cellular hierarchies are not well defined 
in solid organs. However, mounting evidence has shown that CSC are, in fact, present in solid 
tumors, as will be discussed in the following section.  
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Isolation of cancer stem cells in solid tumors 
 
The first demonstration that a specific, identifiable population of cells within a solid 
human tumor was able to isolate the tumor-initiating activity in a xenograft transplantation assay 
occurred in breast cancers (Al-Hajj et al., 2003). In this study, FACS sorting based on the 
expression of cell surface markers CD44 and CD24 demonstrated that only the CD44
+
/CD24
-/low
 
population of cells possessed the capability for self-renewal and tumor-initiation by serial 
transplantation. The transplanted tumors initiated by the CD44
+
/CD24
-/low
 population further 
exhibited differentiation into heterogeneous cell types to regenerate the phenotypic complexity 
observed in the primary tumor. Following this study, CSC have been further identified in other 
solid tumors of the brain (Singh et al., 2004), colon (O’Brien et al., 2007; Ricci-Vitiani et al., 
2007) and pancreas (Li et al., 2007; Hermann et al., 2007) by the prospective isolation with cell 
surface markers. Cell surface markers utilized for isolation of the tumor-initiating, stem-like cells 
in the variety of solid tumors include CD133 (also known as prominin 1) for brain, colon and 
pancreatic cancers, CD44/CD24/ESA (epithelial-specific antigen) for pancreatic cancer, and 
ALDH1 (aldehyde dehydrogenase) as an additional marker for breast cancers (Ginestier et al., 
2007). As observed in AML, the CSC surface markers in solid tumors include those that have 
also been characterized as markers for tissue stem cells present in the corresponding disease 
organ, such as CD133, a marker for NSC (Uchida et al., 2000) and ALDH1 for mammary stem 
cells (Ginestier et al., 2007).  
The gold standard assay for determining CSC activity is the in vivo transplantation assay, 
in which the putative CSC population is orthotopically injected into immunocompromised mice 
(Clarke et al., 2006). Animals are monitored for tumor formation and secondary tumors are 
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analyzed for differentiation capacity and recapitulation of the primary tumor. Serial 
transplantation further validates the self-renewal capability of the CSC present in the tumor 
(Clarke et al., 2006). Limiting dilution transplantation assays can also be carried out to determine 
the number of fractionated cells required for cancer-initiation in vivo (Ginestier et al., 2007; 
O’Brien et al., 2007). Nonetheless, the xenograft assay is not without caveats and limitations. 
Importantly, there are major concerns about the separation of the tumor cells from the 
endogenous stroma, which may prevent engraftment in a foreign microenvironment (Clarke et 
al., 2006). While this issue may be circumvented if the CSC population is niche-independent, the 
frequency of tumor-initiation has been shown to vary greatly depending on the genetic 
background of the recipient mouse (Quintana et al., 2008). The role of the niche is further 
highlighted in cancers that may be induced by an endogenous tumorigenic niche itself (Walkley 
et al., 2007). In addition, the xenograft assays have the technical disadvantage of being slow and 
may take months for tumors develop in vivo following transplantation.  
The prospective isolation of CSC has largely been dependent on cell surface markers 
using markers of normal stem cells, mainly CD133 and CD44/CD24 (Visvader and Lindeman, 
2008), but concerns about the purity of FACS isolated cell populations due to subjective factors 
such as gating or variability in reagents such as antibodies must be considered and marker 
expression may also not be a stable characteristic of the CSC. One possible method for 
circumventing these issues is by increasing specificity by using a combination of markers 
(Medema, 2013). 
Non-adherent sphere formation assays, developed for the isolation of NSC (Reynolds and 
Weiss, 1996), have been a standard assay in isolating and maintaining the growth of brain tumor 
cell stems in vitro (Dirks, 2008). Tumors maintained in serum-free sphere cultures have been 
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shown to represent the characteristics of the original tumor more accurately than serum cultured 
lines (Lee et al., 2006). It has also been reported that neurospheres are not necessarily derived 
from stem cells (Pastrana et al., 2011) and intra-clonal heterogeneity is observed within a 
neurosphere, that may contain stem cells, as well as, more differentiated progenitors (Suslov et 
al., 2002). One must consider the caveats of utilizing a culture-based isolation method, as tissue 
culture-induced alterations may also occur. Nonetheless, in vitro propagation and expansion of 
stem-like cells by sphere formation assays prove to be a valuable method for rapid examination 
of pathways and amenable for genetic manipulation.  
 
Tracking cancer stem cells in vivo 
 
An ideal method to avoid the concerns of separating CSC from its endogenous niche, 
which may lead to culture-induced changes or loss of activity, is by tracking cells in vivo in an 
unperturbed system with viral tagging strategies or knock-in reporter models. (Clevers, 2011). 
While this is not feasible in humans for obvious ethical reasons, in vivo lineage tracing of 
genetically marked cells allows for the observation of progeny derived from a single cell in 
mouse models. Recently, three independent studies demonstrated the presence of endogenous 
tumor-initiating cells by marking a putative stem cell population and tracking the tumor growth 
in vivo, in colon, skin, and brain cancers (Schepers et al., 2012; Driessens et al., 2012; Chen et 
al., 2012). Particularly, in the brain tumor study, Nestin-ΔTK-IRES-GFP expressing stem cells in 
a mouse model of glioblastoma (hGFAP-Cre;Nf1
fl/+
;P53
fl/fl
;Pten
fl/+
), which mark the adult NSC 
in the subventricular zone, were also demonstrated to identify the glioma-initiating stem cells in 
vivo (Chen et al., 2012). Furthermore, ablation of this cell population by treatment with 
ganciclovir led to arrested tumor growth, showing that the hGFAP-expressing stem cells 
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maintained tumor growth. Importantly, following the regression of the tumor with 
chemotherapeutic agent temozolmide (TMZ), tumor regrowth was observed to be initiated by the 
Nestin-ΔTK-IRES-GFP cells. Together, the results from the three independent lineage tracing 
studies provide a convincing demonstration of an endogenous CSC population in solid tumors, as 
the CSC were identified in an unperturbed system in which cells are not removed from 
endogenous niche and transplanted to another species. A question that remains is whether the 
cells being tracked in vivo with the lineage tracing methods are, in fact, the same populations 
being functionally assayed in the xenograft transplantation assays. This will be important in 
determining the validity of transplantation assays that have been being utilized as the gold-
standard method.  
 
Treatment resistance of cancer stem cells 
 
Chemo- and radiotherapy preferentially kill rapidly dividing, cycling cells. If a CSC is 
derived from a rare cell that infrequently enters the cell cycle, such therapies would be relatively 
inefficient or unable to target these cells (Clarke et al., 2006). In fact, normal stem cells exhibit 
properties such as quiescence, expression of ABC (ATP-binding cassette) transporters, active 
DNA-repair, and resistance to apoptosis, rendering them resistant to radiation and toxins (Dean 
et al., 2005). In particularly, high expression of ABC transporters, known for their role in multi-
drug resistance, results in a “side-population” phenotype characterized by efflux of the Hoechst 
dye. In bone marrow, the “side population” contains HSC that are able to reconstitute the 
hematopoietic system. Utilization of the Hoechst dye has also allowed for the early isolation of 
cells with stem-like characteristics from tumor samples (Dean et al., 2005). However, this 
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method isolates a heterogeneous population and subsequent studies have focused on the 
characterization of specific cell-surface markers for the prospective isolation of CSC.  
Both chemo- and radioresistance mechanisms have been observed in the cancer stem-like 
population in hematopoietic cancers and solid tumors. In human AML, the CD34
+
CD38
-
 
leukemia stem cells were more resistant to the chemotherapeutic Ara-C and a greater fraction of 
these cells were found to be quiescent in G0 compared to the CD34
+
CD38
+
 or CD34
-
 cells. 
Secondary transplantation of the Ara-C-surviving CD34
+
CD38
-
 cells suggests that these 
chemoresistant cells can be responsible for tumor relapse (Ishikawa et al., 2007). In breast 
tumors, standard chemotherapy treatment led to an increase in the fraction of CD44
+
CD24
-/low
 
breast CSC and a concurrent increase in mammosphere formation (Li et al., 2008; Yu et al., 
2007) and this was mediated by the reduction of miRNA let7 expression by the breast CSC.  
Several mechanisms have been implicated in the resistance of CSC to ionizing radiation. 
In human glioblastoma primary and xenograft tumors, CD133
+
 glioma stem cells displayed 
increased resistance to ionizing radiation compared to CD133
-
 cells and the CD133
+
 cells that 
survived the radiation were able to initiate tumors with similar potency as untreated cells. This 
survival was mediated by enhanced DNA damage checkpoint activation by the CD133
+
 cells 
(Bao et al., 2006). CD133
+
 cells in medulloblastoma cell lines exhibited greater radioresistance 
than the CD133
-
 counterparts and displayed an increase in CD133 expression in hypoxic 
conditions (Blazek et al., 2007). In a breast cancer model, CSC-enriched populations also 
exhibited less DNA damage after radiation and this was be attributed to lower levels of reactive 
oxygen species (ROS), mediated by the increased expression of antioxidant or anti-ROS genes 
(Diehn et al., 2009).  
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In several mouse models of medulloblastomas, a population of radioresistant CSC was 
identified to be present in the perivascular niche (Hambardzumyan et al., 2008). Upon radiation 
treatment, the bulk of the tumor underwent Trp53-dependent apoptosis. However, a subset of 
nestin-positive cells in the vascular niche was able to survive radiation and undergo cell cycle 
arrest, until they re-entered the cell cycle 72 hours post-treatment and proceeded to proliferate 
and cause tumor recurrence (Hambardzumyan et al., 2008). 
 
Significance and Controversy 
 
 The CSC hypothesis emerged in part from observations that tumors with stem cell-like 
properties have greater resistance to conventional chemo- or radiotherapy, resulting in disease 
recurrence following tumor resection. There are great implications if the CSC hypothesis is true 
and there exists a rare population of cells that are refractory to standard treatments. While 
standard therapies can effectively target the bulk of the tumor, therapies targeting the CSC 
population specifically may be necessary for effective elimination of the tumor and the 
prevention of tumor relapse (Clarke et al., 2006). Therefore, it is crucial to study the mechanisms 
of CSC survival and maintenance. However, this has not been straightforward and controversies 
have been raised regarding the validity of the CSC hypothesis.  
Controversies involving CSC are manifold and reasons include, but are not limited to 
methods of isolation, assays for measuring activity, confusion regarding the definition of CSC 
and whether or not it must be derived from transformed tissue stem cell. Recently, the 
controversy of CSC was fueled by a study showing that a very high frequency (1 in 4) of tumor-
initiating cells were actually present in melanomas when more severely immunocompromised 
recipient animals were utilized (Quintana et al., 2008). This is contrary to the notion that only a 
rare population of cells possesses the capability for tumor-initiation. This would argue that the 
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xenograft transplantation assays have been underestimating the frequency of human CSC when, 
in fact, a much larger proportion of cells have the tumorigenic potential when the appropriate 
environment is provided. This highlights the concerns and caveats regarding the use of xenograft 
transplantation assays as the gold standard for measuring functional CSC activity. Syngeneic 
transplantation assays carried out in mouse models of B and T- cell lymphomas, driven by c-myc 
and N-ras expression by the Eu enhancer also concluded that the tumor-initiating population is 
not as rare as initially expected (>10%) (Kelly et al., 2007). However, in other tumor models of 
leukemia and breast cancer that examined CSC activity with the syngeneic transplantation of the 
prospectively isolated tumor stem cells, the results were consistent with the xenograft studies, 
identifying the tumor-propagating population as a rare population (Guo et al., 2008; Zhang et al., 
2008). These studies demonstrate the variability that occurs depending on the experimental 
context, or alternatively, may be reflecting the biological variability in the frequency that occurs 
between different tumor types or even between individual tumors of the same type. In fact, the 
frequency of leukemia initiating cells can vary up to 500 fold between patients (Bonnet and 
Dick, 1997).  
Current methods of CSC isolation are largely based on FACS isolation with cell surface 
markers. But further complexities in the characterization and the interpretation of CSC 
populations may arise if the CSC are not a stable population, but demonstrate a phenotypic 
plasticity allowing for interconvertibility between CSC and non-CSC (Gupta et al., 2009). If 
CSC are maintained in a stable state with defined properties and pathway dependencies, targeting 
CSC specifically may be a feasible strategy. However if CSC demonstrate “plasticity” during the 
progression of tumorigenesis or during therapeutic challenge, this will have important 
implications for treatment strategies (Jordan, 2009). For example, if dedifferentiation of non-
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stem cancer cells can also lead to the generation of a CSC population, this necessitates the need 
for targeting both the bulk and the stem cell compartment.  
Other controversies have arisen due to confusions regarding the term cancer “stem cell”, 
which have led to the assumption about the cellular origin of these cells, the name suggesting 
that the precursors of CSC are normal tissue stem cells. While it is true that in some cases of 
leukemia, the cell of origin is a transformed stem cell, the assays used to identify CSC are purely 
based on functional tests for tumor-initiation and not intended to imply that they are derived 
from normal stem cells (Jordan, 2009). Despite the many controversies, the CSC hypothesis has 
remained a topic of immense interest and efforts continue to further validate and characterize the 
population of CSC in various tumor types. 
 
Brain tumor stem cells 
 
As previously described, mouse and human NSC when cultured as neurospheres in the 
presence of bFGF and EGF have been shown to maintain the characteristics of clonogenic self-
renewal in vitro and engraftment and multipotent differentiation in vitro and in vivo (Reynolds et 
al., 1992). These methods for studying normal NSC have been employed for the initial 
identification and isolation of human brain tumor stem cells in astrocytomas, glioblastomas and 
medulloblastomas (Singh et al., 2004; Hemmati et al., 2003). Culturing human brain tumors as 
neurospheres in serum-free culture has been shown to better retain and recapitulate the 
characteristics of the primary tumor (Lee et al., 2006), further supporting the neurosphere culture 
as an important method for the characterization and isolation of potential brain tumor stem cells, 
especially in the absence of cell surface markers allowing for the prospective isolation from 
primary tumors.  
 25 
Prospective isolation of tumor cells using NSC markers, such as CD133, has also been 
successfully utilized for the isolation of brain tumor stem cell activity. Specifically, in 
medulloblastoma, as low as 100 CD133-positive cells was shown to initiate a tumor upon 
xenograft transplantation and both classic and desmoplastic histologies have been recapitulated, 
while CD133-negative cells lacked this activity (Singh et al., 2004). Furthermore, 
nestin
+
/CD133
+
 brain CSC have been identified in the perivascular niche, interacting with the 
endothelial cells for maintenance of their stem cell state (Calabrese et al., 2007). A recent 
lineage-tracing study marking nestin
+
-expressing NSC in a glioblastoma model demonstrated the 
ability of these NSC to initiate tumors and importantly, reinitiate tumor formation following 
chemotherapeutic treatment (Chen et al., 2012). An endogenous population of medulloblastoma 
stem cells has yet to be examined with lineage tracing studies. While an embryonic stem (ES) 
cell gene expression profile is enriched in the high grade tumors, which have poor prognoses 
(Ben-Porath et al., 2008), the correlation between the presence of endogenous stem cell 
populations in brain tumors and overall survival has also not been studied. 
 
Ptch1
LacZ/+
;Trp53
-/-
 mouse model of disseminated medulloblastoma with self-
renewing, tumor-initiating cells 
 
Despite the recent advances in the development of subtype-specific tumors, few models 
have examined the phenotypes of dissemination or the population of CSC specifically. This is 
important given that dissemination/metastases is an indicator for poor prognosis and there is 
evidence suggesting CSC can exhibit metastatic capabilities (Hermann et al., 2007). Specifically, 
in pancreatic cancers, the subpopulation of CD133
+
 cells co-expressing CXCR4 (C-X-C 
chemokine receptor type 4) were located at the invasive front of the tumors and exhibited 
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migratory and metastatic characteristics (Hermann et al., 2007). In all tumor subtypes except the 
WNT tumors, which have an overall high rate of survival, in general, patients exhibiting 
dissemination have worse overall survival compared to those without disseminated tumors (Kool 
et al., 2012). A relatively small proportion of patients with SHH tumors exhibit metastases (13% 
in SHH tumors), however, it will be valuable to have models that represent the metastatic 
phenotype given the poor survival of patients with metastases. Although the SHH tumor models 
are well established, the smaller subset of SHH tumors with the metastatic phenotype may not be 
captured in these models and may not uncover the underlying genetic pathways important in 
dissemination and treatment resistance. In one activated Smo model, a homozygous SmoA1 
mutation was shown to result in highly aggressive tumors with leptomeningeal dissemination to 
the brain and spine and the ability to form secondary tumors transplantation, suggestive of a 
tumor-initiating population (Hatton et al., 2008). 
In other models of medulloblastoma-initiating cells, consistent with the identification of 
human CSC in the perivascular niche, a Nestin-positive, radioresistant stem cell population was 
also observed in the perivascular niche in mice (Hambardzumyan et al., 2008). Furthermore, the 
survival of these stem cells following radiation was dependent on activation of the Akt pathway, 
suggesting the inhibition of this pathway as a potential avenue for treatment. Recently, postnatal 
self-renewing CbSC overexpressing c-myc (Pei et al., 2012) or with inactivating mutations of Rb 
and Trp53 (Sutter et al., 2010) have been shown to initiate tumors upon transplantation, 
suggesting the potential role for CbSC transformation for medulloblastoma tumorigenesis. 
 
Ptch1
LacZ/+
;Trp53
-/-
 mouse model of medulloblastoma  
 
 In mice, Ptch1 homozygosity results in embryonic lethality at around E9.0-E10.5, but 
heterozygous Ptch1 mutants develop medulloblastomas histologically similar to human 
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medulloblastomas (Goodrich et al., 1997). The combination of Trp53
-/- 
with the Ptch1
LacZ/+ 
mutation results in a more malignant tumor, accelerating medulloblastoma formation from 10 
months (in Ptch
LacZ/+ 
mice) to 12 weeks and increasing tumor penetrance from 14% to greater 
than 95% (Wetmore et al., 2001). Histological differences are also observed, as the Ptch1
LacZ/+ 
genotype represents a more benign and focal tumor with no dissemination and the 
Ptch1
LacZ/+
;Trp53
-/-
 tumors are more diffuse (C.Lin thesis). Recently, Sleeping Beauty 
transposon mutagenesis in the Ptch1 heterozygous background accelerated tumorigenesis and 
also led to tumors exhibiting leptomeningeal dissemination (Wu et al., 2013), suggestive that 
additional mutations are required for dissemination in the Ptch1 model.  
Our lab further determined that there was a difference in the endogenous stem cell 
activity between the Ptch1
LacZ/+
 and Ptch1
LacZ/+
;Trp53
-/-
 tumors using the serum-free in vitro 
neurosphere assay for self-renewal. Ptch1
LacZ/+
;Trp53
-/-
 tumor cells have been reported to 
undergo changes during adherent, serum-enriched tissue culture, such as downregulation of SHH 
signaling, highlighting concerns that serum-cultured cells in vitro cells may be not representative 
of the original tumors (Sasai et al., 2006). Thus, our lab sought to culture the tumor cells in 
neurosphere conditions to better preserve the in vivo characteristics of the Ptch1
LacZ/+
;Trp53
-/-
 
medulloblastomas, including the potential stem cell population, as the addition of serum leads to 
differentiation or NSC. As described above, this neurosphere culture method is commonly 
utilized for the enrichment of brain tumor stem-like cells. While the prospective isolation of 
tumor stem cells directly from the primary tumor is crucial for further characterization of this 
population, additional markers may need to be identified for the isolation of Ptch1
LacZ/+
;Trp53
-/-
 
tumors stem cells. In the Ptch1 heterozygous mouse model, CD133, the most commonly used 
marker for brain tumors, does not enrich for tumor-initiating capability (Read et al., 2009). One 
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additional marker, CD15, a marker of embryonic and NSC, was previously shown to fractionate 
the cells with tumor-propagating capability (Read et al., 2009; Ward et al., 2009).  
Ptch1
LacZ/+
;Trp53
-/-
 tumors display robust neurosphere formation at a frequency of 
approximately 1/50 in clonal growth conditions (C.Lin thesis). In contrast, Ptch1
LacZ/+
 tumors 
only displayed sporadic, if any, self-renewal activity. In addition, the long term culture of the 
Ptch1
LacZ/+
;Trp53
-/-
 medulloblastoma neurospheres (MBNS) led to the enrichment of self-
renewing cells, with high expression of NSC markers, Sox2 and nestin. Furthermore, tumor-
propagation capability of these Ptch1
LacZ/+
;Trp53
-/-
 MBNS was demonstrated by injections of 
both bulk tumor and neurosphere lines into the cerebella of nude mice (n=5), all of which 
developed cerebellar tumors. Tumor-initiation occurred more rapidly in the MBNS and their 
clonally derived subclones compared to the bulk tumors, suggestive of an enrichment for tumor-
initiation activity. The transplanted tumors displayed dissemination within the brain and 
migration to the olfactory bulb and to the spinal cord. Together, these observations demonstrated 
that a self-renewing, tumor-propagating population can be enriched with in vitro neurosphere 
culture in the disseminated Ptch1
LacZ/+
;Trp53
-/- 
medulloblastoma model. 
 The Ptch1
LacZ/+
;Trp53
-/-
 model suggests that there may be an alternate cell of origin for 
the tumor-initiating cells within SHH-type tumors (C.Lin thesis), distinct from the granule cell  
progenitors, which have been characterized as the cell of origin in this subtype (Schüller et al., 
2008; Yang et al., 2008b). In the Ptch1
LacZ/+
;Trp53
-/-
 animals, self-renewal activity was also 
present at 3 weeks (at a frequency of approximately 1/100), which is beyond the normal 
developmental window for self-renewal, as evident by the lack of neurosphere formation in wild-
type (WT) 3 week animals. These aberrant CbSC, persisting beyond the stages of normal 
cerebellar development in the mutant p53 background, may also result in a tumor-initiating cell 
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population. While normal NSC depend on bFGF and EGF for the maintenance of proliferation 
and self-renewal, the growth factor responsiveness and pathway dependencies of the MBNS 
identified in the Ptch1
LacZ/+
;Trp53
-/-
 model have not been characterized. Data from our lab, 
however, suggest differences in the growth factor dependencies between the MBNS and the 
aberrant CbSC. When the growth factors bFGF and EGF were withdrawn from 3 week old 
Ptch1
LacZ/+
;Trp53
-/-
 aberrant CbSC cultures, the expression of the NSC marker Sox2 was 
reduced. The MBNS, however, are not dependent on exogenous bFGF and EGF, and short-term 
growth factor withdrawal did not affect the expression of Sox2. These data indicate that further 
elucidation of pathways involved in the maintenance of the MBNS enriched from the 
Ptch1
LacZ/+
;Trp53
-/- 
tumors is necessary. In addition, pathways allowing for the aberrant 
persistence of self-renewing, premalignant cells in 3 week Ptch1
LacZ/+
;Trp53
-/-
 animals will shed 
light on the early progression of the tumors.  
 
Research Objectives 
 
In my dissertation, we sought to ask about the mechanisms of stem cell regulation and the 
pathways dependencies of medulloblastoma neurospheres and premalignant tissue stem cells in 
the Ptch1
LacZ/+
;Trp53
-/-
 model. The discovery of reprogramming mechanisms for converting 
somatic cells to a pluripotent embryonic state demonstrated that directed de-differentiation can 
occur through ectopic expression of the transcription factors, Oct4, Sox2, c-myc, and Klf4 
(Takahashi and Yamanaka, 2006); the latter two being notable oncogenes expressed in many 
types of human cancer (Rowland and Peeper, 2006). The intrinsic genetic program of NSC can 
be reprogrammed to an embryonic state with the induction of a single transcription factor, Oct4 
(Kim et al., 2009), possibility because of endogenous expression of Sox2, c-myc and Klf4 (Kim 
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et al., 2008b), as well as reprogramming markers SSEA-1 (CD15) and alkaline phosphatase 
(Kim et al., 2009). In Chapter 2, we show that MBNS are able to rapidly adapt to embryonic 
stem cell culture selection in an in vitro assay for reprogramming. This led to the characterization 
of pluripotency gene Klf4 as a crucial factor in MBNS plasticity and self-renewal, which was 
regulated in a Stat3-independent manner during clonogenic self-renewal.  
While the culture-enriched Ptch1
LacZ/+
;Trp53
-/- 
MBNS exhibit properties of CSC, 
including as long term, clonal self-renewal in vitro and robust tumor-propagation in vivo, the 
lack of a prospective marker for isolation of the tumor-initiating activity precludes us from 
terming these cells as definitive CSC endogenously present in the primary tumors. In Chapter 3, 
we sought to isolate Sox2-expressing cells and characterize Sox2 as a potential marker for the 
prospective isolation tumor stem cells in the Ptch1
LacZ/+
;Trp53
-/- 
model. 
We prospectively isolated the aberrant tissue stem cell population from the Ptch1
LacZ/+
;Trp53
-/-
 
animals using a fluorescent reporter allele of Sox2, a NSC marker, with the goal of characterizing 
pathways involved in the developmental persistence of these cells during tumorigenesis.  
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Chapter 2 : Klf4 maintains the plasticity and self-renewal of 
medulloblastoma neurospheres in a Stat3-independent manner 
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Introduction 
 
The cancer stem cell hypothesis suggests that only a small subpopulation of stem-like 
cells within a tumor have the capability for tumor-initiation and self-renewal. This population of 
cells is associated with greater resistance to conventional therapy, resulting in disease recurrence 
following tumor resection (Clarke et al., 2006). Indeed, brain tumor-initiating cells displaying 
self-renewal and secondary tumor initiation in orthotopic xenografts have been identified in high 
grade human medulloblastomas and glioblastomas (Singh et al., 2003; Galli et al., 2004; 
Hemmati et al., 2003). In mouse medulloblastoma models, while rational pathway inhibitors are 
able to slow tumor growth, they are unable to completely eliminate tumor cells, resulting in 
tumor regrowth (Lau et al., 2012). Consistent with a role for tumor-initiating cells in disease 
relapse, a small population of stem-like cells resistant to radiotherapy has been identified in the 
cerebellar perivascular niche in primary human medulloblastomas (Calabrese et al., 2007) and 
medulloblastoma-prone mice (Hambardzumyan et al., 2008). Therefore, characterization of the 
mechanisms and pathways involved in the maintenance and survival of the population of 
medulloblastoma-initiating cells is critical for the development of effective targeted therapeutics. 
Examination of the common genetic programs and signaling pathways utilized in stem 
cells and cancer cells provide important insights into mechanisms governing cancer stem cells 
(CSC) (Krizhanovsky and Lowe, 2009). For example, in AML, high expression of hematopoietic 
stem cell signatures directly predicts patient survival (Eppert et al., 2011). A study by Kho et al. 
comparing human medulloblastoma gene profiles with expression signatures from the 
developing mouse cerebella observed a high correlation between metastatic human 
medulloblastomas and the postnatal day 5 through day 7 mouse cerebella (Kho et al., 2004), a 
developmental timepoint when the cerebellum is largely undifferentiated and cerebellar stem 
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cells (CbSC) are the most abundant (Lee et al., 2005). Selection for prominin 1 (also known as 
CD133) enriches for a CbSC population co-expressing pluripotency genes Oct4, Nanog, and 
Sox2 and the NSC factors nestin and Bmi1 (Po et al., 2010). Notably, the comparison of gene 
expression profiles of cancers and embryonic stem (ES) cells have also revealed correlations 
between ES cells and poorly differentiated, high-grade human tumors (Wong et al., 2008; Ben-
Porath et al., 2008), including brain tumors (Ben-Porath et al., 2008; Holmberg et al., 2011). 
Together, these studies reveal coordinated patterns of expression of pluripotency factors in CbSC 
and cancers; however the extent to which medulloblastoma-initiating cells rely upon these 
pathways has not been determined.  
Oncogenic reprogramming and dedifferentiation of tumor cells has been proposed as a 
mechanism for generating and maintaining CSC (Krizhanovsky and Lowe, 2009; Hanahan and 
Weinberg, 2011). We were interested to test whether medulloblastoma neurospheres (MBNS) 
from metastatic medulloblastomas exhibit signs of endogenous reprogramming and dependency 
on these pathways. To approach this question, we studied the highly malignant 
Ptch1
LacZ/+
;Trp53
-/-
 mouse medulloblastoma model (Wetmore et al., 2001). Ptch1
+/-
 
medulloblastoma cells have previously been shown to undergo reprogramming following 
somatic nuclear transfer into mouse oocytes (Li et al., 2003), showing that the cancer genomes 
can be epigenetically reprogrammed by the oocyte to reverse the tumorigenic activity and restore 
normal early development. Self-renewing, tumor-initiating neurospheres enriched from 
Ptch1
LacZ/+
;Trp53
-/-
  tumors were used in an in vitro assay for reprogramming to assess 
adaptation to embryonic stem cell culture conditions, which would not normally be expected to 
support NSC growth in the absence of ectopic reprogramming factors, due to the differentiation 
factors present in serum (Reynolds et al., 1992). The Ptch1
LacZ/+
;Trp53
-/-
 MBNS demonstrated 
 34 
plasticity and maintained growth and self-renewal in ES culture conditions. Furthermore, given 
the crucial function Klf4 plays in somatic reprogramming (Yang et al., 2010b) and mouse ES cell 
self-renewal (Zhang et al., 2010), we examined the role of Klf4 in maintaining the plasticity and 
self-renewal of the Ptch1
LacZ/+
;Trp53
-/-
 MBNS. We observed that Klf4 is critical in maintaining 
both the plasticity of the Ptch1
LacZ/+
;Trp53
-/-
 MBNS in ES culture conditions and clonogenic 
growth as self-renewing neurospheres. In addition, Klf4, a known Stat3-target, was regulated in a 
Stat3-independent manner during clonogenic growth. 
 
Results 
 
Neurosphere culture-enriched Ptch1
LacZ/+
;Trp53
-/-
 medulloblastoma line exhibits 
characteristics of self-renewal and tumor-propagation 
 CSC are functionally defined as a cell within a tumor with the capability for indefinite 
self-renewal and tumor initiation and recapitulation of the primary tumor upon secondary 
transplantation (Clarke et al., 2006). We first sought to functionally assess if stem-like cells 
cultured from a primary Ptch1
LacZ/+
;Trp53
-/-
 mouse medulloblastoma exhibit properties of CSC. 
Self-renewing cells were enriched from primary tumors using neurosphere cultures in serum-free 
media containing bFGF and EGF (Reynolds and Weiss, 1996), as this approach has been 
previously utilized for culturing human brain tumor stem cells (Hemmati et al., 2003; Galli et al., 
2004; Singh et al., 2003) and has been shown to preserve the genotype, gene expression and 
histopathology of tumor-propagating cells from human brain tumors (Lee et al., 2006). In 
addition, traditional serum-based cell cultures of Ptch1
LacZ/+
;Trp53
-/-
 mouse medulloblastomas 
have been reported to alter the properties of the original tumor and suppress the Shh pathway 
activity (Sasai et al., 2006) and serum leads to the terminal differentiation of NSC (Reynolds et 
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al., 1992; Gage et al., 1995). Ptch1
LacZ/+
;Trp53
-/-
 mouse medulloblastoma neurosphere lines were 
maintained by dissociating and serially passaging in bulk cultures for more than 50 passages or 
clonally expanded as subclones. The long-term cultured Ptch1
LacZ/+
;Trp53
-/-
 MBNS were 
enriched for self-renewal activity ten-fold, compared to the primary tumor neurospheres and 
maintained elevated expression of Shh pathway target genes Gli1 and Gli2 (C.Lin thesis). As 
NSC surface markers CD15 and CD133 have been shown to mark tumor-propagating cells in 
mouse Ptch1
LacZ/+ 
tumors (Read et al., 2009) and human medulloblastomas (Singh et al., 2004) 
respectively, we carried out flow cytometry to assess expression of these markers in a primary 
tumor and the neurosphere culture-enriched Ptch1
LacZ/+
;Trp53
-/-
 cells. CD15 expression in the 
MBNS overlapped with the highest expressing cells within the heterogeneous primary tumor, 
whereas CD133 levels were elevated in the MBNS (Figure 2-1). The Ptch1
LacZ/+
;Trp53
-/-
 MBNS 
were also enriched in the expression of NSC markers nestin and Sox2, as shown by 
immunostaining of neurospheres (C. Lin thesis).  
 
 
Figure 2-1 A Ptch1
LacZ/+
;Trp53
-/-
 medulloblastoma-derived neurosphere line is enriched for NSC cell marker 
expression in comparison to the primary tumor 
FACS analyses of cell surface markers CD15 and CD133 in primary tumors and a Ptch1
LacZ/+
;Trp53
-/-
 
medulloblastoma neurosphere (MBNS) line show an enrichment of the expression of these markers in the culture-
enriched line. 
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To determine if these self-renewing MBNS were capable of tumor-initiation in vivo, 
intracerebellar injections were carried out using 10
4
, 3 x10
4 
and 10
5
 cells (n= 2, 3, 3 
respectively). Injected animals were sacrificed upon manifestation of neurological symptoms 
such as hydrocephaly, ataxia, or motor dysfunction and tumors that caused morbidity were 
observed within six weeks in all animals. X-Gal staining to detect Ptch1
LacZ
 expression in a 
primary tumor (Figure 2-2a) and the allograft tumors (Figure 2-2d) confirmed tumor engraftment 
in the cerebella. Upon cerebellar transplantation of the MBNS, dissemination to the olfactory 
bulb was also observed 60% of the time (C. Lin thesis). A comparative histological analyses of a 
primary Ptch1
LacZ/+
;Trp53
-/-
 medulloblastoma (Figure 2-2b, c) and a secondary tumor initiated 
with the injection of 10,000 MBNS cells (Figure 2-2e, f) demonstrated consistent architecture in 
the primary and secondary tumors, which were typified by dense cells with angulated nuclei and 
little cytoplasm. The secondary tumors, however, appeared to have a higher mitotic rate and 
were marked by less differentiated cells with prominent nucleoli and minimal cytoplasm. 
Furthermore, our lab has observed that when the same number of primary Ptch1
LacZ/+
;Trp53
-/-
 
medulloblastoma cells and culture-enriched MBNS were injected, the MBNS-injected animals 
display accelerated tumor formation (C. Lin thesis). Together, these results show that 
Ptch1
LacZ/+
;Trp53
-/-
 MBNS exhibit properties of self-renewal and secondary tumor propagation.  
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Figure 2-2 A neurosphere line derived from a primary Ptch1
LacZ/+
;Trp53
-/-
 medulloblastoma is able to 
propagate secondary tumors recapitulating the primary tumor 
(a) X-gal stained sagittal section of a primary Ptch1
LacZ/+
;Trp53
-/-
 medulloblastoma. (b-c) Hematoxylin and eosin 
(H&E) stained section of the primary tumor. (d) X-gal stained sagittal section of a secondary tumor formed 4 weeks 
after intracranially injecting 10,000 Ptch1
LacZ/+
;Trp53
-/-
 MBNS into nude mice. (e-f) H&E stained sections of the 
secondary tumor show that the Ptch1
LacZ/+
;Trp53
-/-
 MBNS can propagate a tumor recapitulating the histology of the 
primary tumor. Scale bars in (b) and (e) are 500um; (c) and (f) are 100um. The white boxes in (b) and (e) indicate 
the sections enlarged in (c) and (f), respectively. 
 
Phenotypic conversion of Ptch1
LacZ/+
;Trp53
-/-
 MBNS grown in ES cell culture conditions 
We established an in vitro reprogramming assay that would test the responsiveness of 
MBNS to fetal bovine serum (FBS) by growth under clonal culture conditions established for ES 
cells. NSC differentiate upon exposure to FBS (Reynolds et al., 1992; Gage et al., 1995), 
whereas embryonic stem (ES) cells maintain pluripotency in media containing FBS and leukemia 
inhibitory factor (LIF). To examine reprogramming activity in Ptch1
LacZ/+
;Trp53
-/-
 MBNS, we 
plated the MBNS in ES culture conditions and monitored ES-like colony formation 
morphologically and quantified colonies expressing the ES cell marker alkaline phosphatase 
(AP) (Figure 2-3a). 
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Figure 2-3 MBNS exhibit growth as alkaline phosphatase-positive colonies in ES cell culture conditions.  
(a) Schematic of the in vitro assay for plasticity, in which Ptch1
LacZ/+
;Trp53
-/-
 MBNS cells were plated in low 
density (1500 cell/ml) in ES cell culture conditions containing serum, mouse embryonic fibroblast (MEF) feeders, 
and leukemia inhibitory factor (LIF). Control conversion experiments were carried out with primary cerebellar 
neurospheres (NS) enriched from postnatal day 5 (P5) and day 7 (P7) wild-type (WT) and P5 Ptch1
LacZ/+
;Trp53
-/-
 
(Ptc
+/-
; p53
-/-
) cerebella. (b) Phase-contrast image of a Ptch1
LacZ/+
;Trp53
-/-
 MBNS grown in suspension culture. (c) 
Phase-contrast image of adherent MBNS colony formation in ES culture conditions, 6 days post-plating. (d) 
Adherent MBNS colonies in ES culture conditions stained for ES cell marker, alkaline phosphatase (AP). (e) 
Homogenously AP-positive clones were identified and quantitated from five independent conversion experiments 
with the Ptch1
LacZ/+
;Trp53
-/-
 MBNS line. There was no observable colony formation with the cerebellar 
neurospheres. 
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The Ptch1
LacZ/+
;Trp53
-/-
 MBNS, which are maintained in media containing bFGF and 
EGF (Figure 2-3b) were dissociated and plated at low-density (1500 cells/ml) in ES cell culture 
conditions. Within 6 days, colonies with an ES cell-like morphology were observed and AP-
positive staining was observed at a frequency of 2.33.2% (Figure 2-3c, d). By contrast, control 
CbSC also enriched by NS culture from wild-type (WT) postnatal day 5 and day 7 mice or 
postnatal day 7 Ptch1
LacZ/+
;Trp53
-/-
 mice yielded no colonies in this assay (Figure 2-3e), 
suggesting a tumor-specific plasticity and resistance to differentiation allowing for the growth 
and maintenance of self-renewal in ES conditions.  
The MBNS colonies from this conversion assay were clonally expanded and generated 
subclones that retained ES colony morphology and maintained stable AP expression for more 
than 15 passages (passage 7 subclone is shown in Figure 2-4a). The AP
+
 MBNS also showed 
strong X-Gal staining from the Ptch1
LacZ
 allele (Figure 2-4a), likely due to the loss of 
heterozygosity of the WT Ptch1 allele (C. Lin thesis). To further determine if the phenotypic 
plasticity of the Ptch1
LacZ/+
;Trp53
-/-
 MBNS, as exhibited by the conversion of MBNS into AP
+
 
colonies in ES culture conditions in vitro, expanded the developmental potency of these cells, we 
examined the gene expression of pluripotency and reprogramming genes Oct4 and Nanog. 
Stochastic expression of Oct4 was observed in one AP
+
 MBNS subclone and Nanog expression 
was present in the parental MBNS and maintained in the AP
+
 MBNS (Figure 2-4b). In contrast, 
the Ptch1
LacZ/+
;Trp53
-/-
 tumors had undetectable or relatively lower levels of Oct4 and Nanog, 
respectively.  
To test if the phenotypic conversion in ES conditions and stochastic Oct4 expression led 
to an expanded developmental potency of the MBNS in vivo, teratoma assays were carried out by  
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Figure 2-4 AP
+
 MBNS subclones maintain ES-like morphology and exhibit stochastic expression of 
pluripotency genes 
(a) AP and X-Gal stain of Ptch1
LacZ/+
;Trp53
-/-
 ES cells and AP
+
 MBNS subclone (passage 7). (b) RT-PCR of bulk 
Ptch1
LacZ/+
;Trp53
-/-
 tumors, MBNS, and AP
+ 
MBNS  shows sporadic expression of pluripotency factor Oct4 in the 
AP
+
 MBNS. Nanog expression is present in the parental MBNS line and maintained in the AP+ MBNS. NuBP 
(Nucleotide binding protein) is shown as a loading control. 
 
the injection of 10
6
 Ptch1
LacZ/+
;Trp53
-/-
 MBNS and AP
+
 MBNS cells into the flanks of nude mice 
and monitored for tumor formation, using Ptch1
LacZ/+
;Trp53
-/- 
ES cells as a control. While 
intracerebellar injections of 10
4
 Ptch1
LacZ/+
;Trp53
-/-
 MBNS led to robust tumor formation 
causing morbidity by six weeks, the subcutaneous injection of 10
6 
MBNS and AP
+
 MBNS cells 
resulted in small tumors, all of which were significantly smaller than the ES-derived teratomas 
(Figure 2-5).  
Histological analyses showed that the Ptch1
LacZ/+
;Trp53
-/-
 ES cell-derived teratomas 
(n=3) were predominantly composed of immature neuroectodermal cells and marked by 
neuroblasts, but displayed no evidence for endoderm or mesodermal cell types. Nonetheless, the 
ES-derived tumors exhibited the greatest cell type-diversity between the three cell types injected 
(Figure 2-6). Tumors formed by subcutaneous injection of the MBNS (n=5) were also 
neuroblastic in nature, but was comprised of more mature, intermediate-sized cells with vacuoles 
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Figure 2-5 AP
+
 MBNS cells do not form teratomas as robustly as ES cells 
(a) X-gal stained tumors dissected from the flanks of nude mice subcutaneously injected with 10
6
 MBNS, AP
+ 
MBNS, or Ptch1
LacZ/+
;Trp53
-/- 
ES cells. Tumors were isolated 3 weeks post-injection. (b) Ptch1
LacZ/+
;Trp53
-/-  
ES-
derived tumors were significantly larger than the MBNS and AP
+
 MBNS tumors (p<0.01 by one-way ANOVA with 
a Bonferroni post test). (c) After measuring the length (mm) and width (mm) of the tumors, tumor volume (mm
3
) 
was calculated by length x width x width. The volumes of the ES-derived tumors were significantly higher than the 
MBNS tumors (p<0.01) and AP
+
MBNS tumors (p<0.05 by one-way ANOVA with a Bonferroni post test). Average 
weight and volume of isolated tumors are represented as mean±sem. 
 
 (Figure 2-6). Interestingly, the AP
+
 MBNS-derived tumors (n=5) displayed an intermediate 
histology, with a predominance of immature hyperchromatic, nucleolated cells with scant 
cytoplasm that form sheets and rests. Interspersed between this major cell population, however, 
were more mature regions resembling the cells predominantly present in the MBNS-derived 
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tumors. While there is no evidence of acquired pluripotency in the AP
+
 MBNS, which display a 
phenotypic adaptation in the ES culture conditions, these results suggest that the AP
+
 MBNS are 
able to exhibit a cellular plasticity to initiate distinct tumors less differentiated than the MBNS-
derived tumors. 
 
Figure 2-6 AP
+
 MBNS-derived teratomas are histologically distinct from the parental MBNS-derived tumors 
Representative images of H&E stained sections of tumors isolated from the teratoma assay, carried out by injecting 
10
6
 MBNS (n=5), AP
+
 MBNS (n=5) or Ptch1
LacZ/+
;Trp53
-/-
 ES cells (n=3) into the flanks of nude mice and 
monitored for tumor formation for 3 weeks, are shown. Mature, intermediate sized cells with cytoplasmic vacuoles 
are indicated with the yellow arrowheads in both the MBNS and AP
+
 MBNS teratomas. The major cell type in the 
AP
+
 MBNS teratomas, which are the hyperchromatic cells with scant cytoplasm are observed in the left half of the 
represented AP
+
 MBNS image and cells in the right half are more histologically similar to the MBNS-derived 
tumors. A neuroectodermal structure is indicated with the black arrow in the ES teratoma. Scale bars are 100um.  
 43 
 
Klf4 mediates MBNS plasticity during conversion into ES culture conditions 
 
Since the MBNS were converted in ES culture conditions without the induction of 
exogenous genes, we wanted to determine if epigenetic changes were involved in mediating the 
MBNS plasticity. We analyzed DNA methylation in the promoters and 5’ regulatory regions of 
pluripotency genes Oct4, Nanog, Klf4, Sox2, c-myc and Stat3 with a quantitative, bisulfite-based 
mass spectrometry methylation assay. In cancers, methylation alternations have been reported to 
occur specifically in CpG island shores, located up to 2kb upstream of the promoter CpG islands 
and are associated with aberrant gene expression (Irizarry et al., 2009). The average methylation 
frequency across the CpGs in the regions assayed was significantly different between the MBNS 
and AP
+
 MBNS in the Klf4 and Sox2 CpG island shores. The most significant differential 
methylation was observed in the Klf4 CpG island shore, with 70.7% methylation in the MBNS 
and a reduction to 34.2% in the AP
+
 MBNS (Figure 2-7). Reduced methylation was observed in 
each individual CpG in this Klf4 regulatory region in the AP
+
 MBNS (Figure 2-8). CpG 
methylation in the Sox2 CpG island shore was also reduced in the AP
+
 MBNS compared to the 
MBNS, to a lesser degree (40.9% in the MBNS vs. 30.7% in the AP
+
 MBNS). The CpG islands 
directly upstream of the transcriptional start site (TSS) in the Klf4 and Sox2 promoters were not 
analyzed by the methylation assay. The average methylation remained unchanged in the other 
pluripotency genes, as the promoters of c-myc and Stat3 remained hypomethylated and Nanog 
remained hypermethylated. The levels of CpG methylation in the Oct4 promoter also remained 
similar between the MBNS and the AP
+
 MBNS. These results suggest a plasticity in the 
epigenetic regulation of the CpG island shores of the pluripotency genes Klf4 and Sox2 during 
the conversion of MBNS into ES culture conditions. 
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Figure 2-7 CpGs in the 5’ regulatory regions of Klf4 and Sox2 are differentially methylated between the 
MBNS and AP+ MBNS  
(a) Methylation analyses of the CpGs in the promoters and 5’ regulatory regions of pluripotency genes were carried 
out by quantitative mass spectrometry, in the parental MBNS line and three AP
+ 
MBNS subclones. Average 
methylation frequencies across the regions analyzed are plotted as mean+sem. Differential methylation is observed 
in the 5’ regulatory regions between the MBNS and the AP+ MBNS in Klf4 (p<0.0001) and Sox2 (p<0.01), as 
determined by two-way ANOVA with a Bonferroni multiple comparisons test. In the right panel, a schematic of the 
promoter and upstream regions of the pluripotency genes indicating the locations of the CpGs analyzed (vertical 
hash marks) is represented. The methylation analyses for Klf4 and Sox2 only included the CpGs in the 5’ regulatory 
regions (CpG island shores), as indicated by the black bars. 
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Figure 2-8 Quantitative methylation analyses of individual CpGs in the 5’ regulatory regions and promoters 
of pluripotency genes in MBNS and AP
+ 
MBNS show differential methylation in Klf4 and Sox2  
The frequency of methylation at each CpG analyzed is denoted by circles (MBNS) or open squares (AP
+
 MBNS). 
Genomic coordinates are indicated on the x-axis. Vertical hashes in the Klf4 and Sox2 promoters indicate CpGs that 
were not analyzed in the methylation array. 
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Figure 2-9 Klf4 mediates MBNS plasticity for conversion into ES culture conditions 
(a) Expression analyses of Klf4 and Sox2 by gel-based RT-PCR. (b) Schematic of the lentiviral vector pSicoR 
(Ventura et al., 2004), which was modified for puromycin selection (Puro
R
) and shRNA expression driven by a 
ubiquitin (Ub) promoter. (c) Klf4 knockdown (kd) MBNS were converted into ES cell culture conditions and 
monitored for AP
+ 
colony formation, as described in Figure 2-3a. (d) Significant reduction in AP
+
 colony formation 
is observed in the shKlf4 MBNS (p=0.018 by unpaired t-test). Representative images of AP
+
 colonies formed are 
shown. 
 
Klf4 expression is reported to abrogate the requirement for LIF to maintain mouse ES 
cells in an undifferentiated state (Zhang et al., 2010) and gel-based RT-PCR confirmed the 
expression of Klf4 transcript in the AP
+
 MBNS, as well as the parental MBNS (Figure 2-9a). 
Although not quantitative, Klf4 was also further examined because Sox2 expression appeared to 
be reduced in the AP
+
 MBNS (Figure 2-9a). Therefore, we next asked if exogenous LIF in the 
ES media was required for the initiation and the maintenance of the AP
+
 MBNS colony 
formation. To determine if exogenous LIF was required for the initiation of the conversion in the 
ES culture condition, we carried out the in vitro reprogramming assay in the presence and 
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absence of LIF with an AP
+
 MBNS subclone and observed no significant difference in the AP
+
 
colony formation (Figure 2-10a, b). However, in the absence of MEFs, which is known to 
provide soluble factors including LIF, while clusters of cells were present, no AP
+
 colony 
formation was observed. To test if exogenous LIF was necessary for the maintenance of self-
renewal and colony formation, a clonogenic plating efficiency assay was carried out in the 
presence and absence of exogenous LIF. AP
+ 
colony formation was not affected by the removal 
of exogenous LIF (Figure 2-10c,d). When we further eliminate a potential source of LIF by 
 
 
Figure 2-10 Exogenous LIF is not required for the conversion or maintenance of MBNS in ES cell conditions 
(a) The conversion of MBNS into ES cell culture conditions was carried out in the presence and absence of both LIF 
and MEFs. (b) Quantification of AP
+
 colony formation shows no observable colony formation in the absence of 
MEFs. With MEFs, no significant difference is observed in the AP
+
 colony formation with or without LIF. (c) A 
stable AP
+ 
MBNS subclone line was assayed for clonogenic plating efficiency in the absence and presence LIF 
and/or MEFs. (d) AP-positive colonies were quantitated by ImageJ analyses, which show no significant difference in 
colony formation in the absence of LIF. 
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carrying out the plating efficiency assay in the absence of MEFs, although the overall frequency 
of colony formation was reduced, no significant difference was observed in the frequency of 
colony formation in the absence of LIF (Figure 2-10c, d). 
To test if the expression of Klf4 (Figure 2-9a) was functionally involved in the plasticity 
of the MBNS during the conversion into ES culture conditions, we knocked down Klf4 with a 
lentivirally-encoded shRNA against Klf4 (Figure 2-9b; Table 1) and 3 days post-infection, the in 
vitro reprogramming assay was carried out (Figure 2-9c). AP
+
 MBNS colony formation was 
significantly reduced with the Klf4 knockdown (kd) (Figure 2-9d), suggesting that Klf4 was 
functionally important in mediating MBNS plasticity and colony formation in ES culture 
conditions. 
Table 1. Hairpin sequences of shKlf4 
 
Position indicates the first nucleotide position site where the shRNA binds in the target sequence. Scores as 
determined by two rule-based design algorithms, DSIR (http://biodev.extra.cea.fr/DSIR/) and pSicoOligomaker 1.5 
(http://web.mit.edu/jacks-lab/protocols/pSico.html). The predicated efficacy threshold value is set at 90 in DSIR. A 
Oligomaker score of greater than 6 is reported to have ~90% chance of silencing the target (Reynolds et al., 2004). 
 
Klf4 is important for the self-renewal of MBNS 
As Klf4 expression is also observed in the parental MBNS prior to conversion into ES 
conditions (Figure 2-9a), we next examined the role of Klf4 directly in the MBNS. Quantitative 
RT-PCR shows that Klf4 expression is significantly increased in the MBNS compared to WT 
cerebellum (Cb), Ptch1
LacZ/+
, and Ptch1
LacZ/+
;Trp53
-/-
 tumors, with a 2.3 fold enrichment 
compared to the WT Cb (Figure 2-11a). To directly test the functional role of Klf4 in the MBNS, 
we knocked down Klf4 with two independent hairpins (Table 1), to levels 20-40% of the control 
levels (Figure 2-11b) and carried out a clonal density NS formation assay, in which shKlf4  
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Figure 2-11 Klf4 kd leads to a reduction in MBNS self-renewal 
(a) Expression of Klf4 mRNA is significantly upregulated in the MBNS compared to wild-type cerebellum (WT 
Cb), Ptch1
LacZ/+
 tumors (Ptc Tu), and Ptch1
LacZ/+
;Trp53
-/-
 (Ptc;p53 Tu), as measured by quantitative RT-PCR 
(p<0.05 by one-way ANOVA with a Bonferroni post test). (b) Expression analyses of Klf4, Stat3 in the d3 post-
infection shKlf4 MBNS by quantitative RT-PCR confirm kd of Klf4 with two independent hairpins (n=3; p<0.001 
by one-way ANOVA with a Dunnett post test). shKlf4#1 does not affect the expression of Stat3 but shKlf4#2 
reduces Stat3 expression by about 25% (p<0.01 by two-way ANOVA with a Dunnett post test). (c) Klf4 kd resulted 
in the significant reduction of self-renewal in the clonal density (100 cell/ml) 6-well NS formation assay. The 
efficiency of NS formation was expressed relative to the vector control. (n=3; 6 wells quantified per shRNA per 
experiment; p<0.001 by one-way ANOVA with a Dunnett post test). Representative images of wells from the NS 
formation assay quantitated by ImageJ are shown. (d) Clonogenic limiting dilution assays (Tropepe et al., 1999) 
were carried out and self-renewal indexes of the shKlf4 MBNS were determined by extreme limiting dilution 
analysis (ELDA) (Hu and Smyth, 2009). 95% confidence intervals (CI) are indicated by the dotted lines. P-values 
are determined by tests for pair-wise differences between the vector control and each of the shRNAs by ELDA. All 
values are represented as mean±s.e.m.  
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Figure 2-11 (Continued) 
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MBNS were plated at a cell density of 100cells/ml, a density ten-fold lower than what is required 
to ensure a clonal event (Coles-Takabe et al., 2008). When NS formation was quantified 5 days 
later, Klf4 kd resulted in a 50-65% reduction in the efficiency of NS formation in the MBNS 
(Figure 2-11c). The role of Klf4 in MBNS self-renewal was further confirmed with a limiting 
dilution assay, where 0.3, 1, 3, 10, and 30 cells were plated per well and assayed for NS 
formation to determine the frequency of self-renewing cells in the shKlf4 MBNS (Tropepe et al., 
1999). Extreme limiting dilution analyses (ELDA) (Hu and Smyth, 2009), determined that the 
self-renewal index was significantly decreased, from 1 in 7.6 cells in the control vector to 1 in 
29.4 cells with shKlf4 #1 and 1 in 16.9 cells with shKlf4 #2 (Figure 2-11d; Table 1). Together, 
these results support the crucial role of Klf4 in the mediating MBNS plasticity during conversion 
into ES culture conditions and in the maintenance of clonogenic self-renewal as neurospheres. 
 
Stat3 signaling is endogenously activated in MBNS 
 
To further gain an understanding of the upstream pathways activating Klf4 expression in 
the MBNS, we asked if the Stat3 pathway was involved, as Klf4 is a known downstream target of 
Stat3 (Niwa et al., 2009; Bourillot et al., 2009; Hall et al., 2009). Furthermore, given that 
exogenous LIF was not required for the initiation and maintenance of the AP
+
 MBNS (Figure 2-
10), we also hypothesized that downstream Stat3 signaling may be endogenously activated or 
deregulated in the MBNS and subsequently mediating the expression of Klf4 downstream. Stat3 
pathway activation is also known to maintain the self-renewal of ES cells (Niwa et al., 1998) and 
the survival of NSC (Androutsellis-Theotokis et al., 2006; Yoshimatsu et al., 2006). 
Since Stat3 expression is modulated by an autoregulatory loop (Ichiba et al., 1998) and 
increased levels of Stat3 mRNA reflect Stat3 pathway activity, we first compared Stat3 mRNA 
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expression among tissues and stem cells from WT or Ptch1
LacZ/+
;Trp53
-/-
 mice using quantitative 
RT-PCR. Stat3 expression in the MBNS was greater than 20-fold higher than the WT Cb and 
significantly higher compared to Ptch1
LacZ/+
;Trp53
-/-
 ES cells and tumors (Figure 2-12a). Stat3 
mRNA levels also showed a 15-fold increase in WT P7 CbSC compared to the WT P7 cerebella, 
consistent with the known developmental role of Stat3 in NSC. The expression levels between 
the WT P7 CbSC and MBNS, however, were not significantly different, suggesting that Stat3 
upregulation alone is not sufficient for AP
+
 colony formation in ES conditions. 
 
Figure 2-12 Stat3 is endogenously activated in MBNS 
(a) Expression of Stat3 mRNA in Ptch1
LacZ/+
;Trp53
-/-
 (Ptc;p53) ES (n=3) cells, MBNS (n=8), WT P7 cerebellar stem 
cells (WT P7 1°NS) (n=5), and Ptch1
LacZ/+
;Trp53
-/-
 (Ptc;p53) tumors (n=5) compared to wild-type cerebellum (WT 
Cb) (n=4), as measured by quantitative RT-PCR. All samples are represented as fold change in expression relative 
to the WT Cb, which is normalized to 1. Significant upregulation of Stat3 is observed in the MBNS compared to 
Ptch1
LacZ/+
;Trp53
-/-
 ES cells (p<0.01), WT Cb (p<0.001), Ptch1
LacZ/+
;Trp53
-/-
 tumor (p<0.001). Stat3 is upregulated 
in the WT P7 1°NS compared to the WT cerebellum (p<0.05), Ptch1
LacZ/+
;Trp53
-/-
 tumor (p<0.05). Statistical 
significance was determined by one-way ANOVA with a Bonferroni post test. (b) Western blot of protein lysates 
from MBNS in NS media, AP
+
 MBNS in ES culture conditions, tissues from WT Cb, and Ptc;p53 tumors with 
pSer727, pTyr705, and total Stat3-specific antibodies. ES cells were used as a positive control for Stat3 activation. 
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Stat3 pathway activation is directly governed by phosphorylation states, such as in NSC, 
where pSer727 is essential for survival and pTyr705 leads to differentiation (Androutsellis-
Theotokis et al., 2006). To address whether alterations in Stat3 phosphorylation might account 
for the relative contribution of these mechanisms in MBNS, we performed western blotting with 
phospho-specific Stat3 antibodies. The results showed activation of both phosphorylated forms 
of Stat3 in the MBNS cultured in NS media and ES conditions, with robust activation of pSer727 
Stat3 (Figure 2-12b). WT Cb and Ptch1
LacZ/+
;Trp53
-/-
 tumors, however, showed relatively lower 
levels of pSer727 and total Stat3. These results show that the Stat3 signaling pathway is 
constitutively activated in the MBNS, as indicated by both transcriptional upregulation and 
activation of Stat3 by phosphorylation, especially at pSer727. 
To assess the signaling pathways involved in the constitutive Stat3 pathway activation, 
we treated MBNS with kinase inhibitors with targets implicated in medulloblastoma stem cells 
(Hambardzumyan et al., 2008), the activation of Stat3 signaling in cortical NSC (Androutsellis-
Theotokis et al., 2006),  as well as Stat3 phosphorylation in other cellular contexts (Stephens et 
al., 1998; Yokogami et al., 2000; Wierenga et al., 2003) (Figure 2-13). Activation of 
PI3K/Akt/mTOR signaling confers radioresistance and survival to medulloblastoma cells in the 
perivascular niche (Hambardzumyan et al., 2008). In cortical NSC, Notch signaling also 
converges on Akt/mTOR pathway activation for subsequent phosphorylation of Ser727 Stat3 and 
NSC survival (Androutsellis-Theotokis et al., 2006). Human medulloblastomas have constitutive 
activation of Stat3 signaling (Schaefer et al., 2002), as well as autocrine production of LIF, a 
major activator of the Jak/Stat signaling pathway (Liu et al., 1999). While Mek1/2 inhibition has 
been observed to inhibit the migration of a medulloblastoma cell line in vitro (MacDonald et al., 
2001), the involvement of Stat3 has not been examined. 
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Figure 2-13 Pathways of Stat3 activation and kinase inhibitors used for the treatment of MBNS 
Schematic showing the differential roles of phospho-Ser727 Stat3 in survival and phospho-Tyr705 Stat3 in the 
differentiation of NSC, adapted from Androutsellis-Theotokis, Leker et al. (2006). MBNS were treated with small 
molecule inhibitors of kinases implicated in the activation of pStat3. 
 
Consistent with canonical Stat3 activation, Jak inhibition robustly reduced pTyr705 Stat3 
activation without affecting pSer727 Stat3 levels  (Figure 2-14a, b). By contrast, Mek1/2 
inhibition, validated by monitoring pErk1/2 levels (Figure 2-14a), caused a modest but 
significant and reproducible 30% decrease in pSer727 Stat3 levels (Figure 2-14a, b). Inhibitors 
of PI3K or mTOR did not significantly alter either pSer727 or pTyr705 levels. Analysis of Stat3 
target gene expression confirmed these results, with Jak inhibition showing reduced Socs3 and 
Stat3 levels within 20 hours (Figure 2-14c). Socs3, a direct target of Stat3, is a key response gene 
in Stat3 signaling (Auernhammer et al., 1999) and Stat3 regulates its own expression (Ichiba et 
al., 1998). At 20 hours, however, expression levels of the downstream target Klf4 (Hall et al., 
2009; Bourillot et al., 2009) were not affected. These results suggest distinct roles for Jak and 
Mek signaling pathways during Stat3 activation in MBNS. 
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Figure 2-14 pTyr705 and pSer727 Stat3 are differentially regulated by Jak and Mek signaling in the MBNS 
 (a) Western blot of protein lysates from MBNS treated with inhibitors of PI3K (10uM LY294002), Mek1/2 (10uM 
U0126), mTOR (50nM Rapamycin) and Jak (1uM Jak inhibitor 1) for 3 hours. A representative western  
blot from three experiments is shown. (b) Quantification of three independent western blots by densitometry 
analyses with ImageJ shows significant reduction of pSer727 Stat3 with Mek inhibition (p<0.0001) and pTyr705 
Stat3 with Jak inhibition (p<0.01). (c) Expression analyses of Stat3 and downstream targets Socs3 and Klf4, by 
quantitative RT-PCR, 20 hours post-inhibitor treatment show that Stat3 expression is significantly increased with 
mTOR inhibition (p<0.01) and decreased with Jak inhibition (p<0.05). Socs3 expression is significantly decreased 
with Jak inhibition (p<0.01). Klf4 expression is not significantly altered with the treatment of any inhibitors. 
Statistical significance was determined by one-way ANOVA with a Dunnett post test 
Combination Jak and Mek inhibition leads to the reduction of MBNS survival 
 
 To further inhibit both phosphorylated forms of Stat3, we treated the MBNS with both 
the Jak inhibitor and Mek inhibitor (U0126), which we have shown to modulate Tyr705 and 
pSer727 Stat3 phosphorylation, respectively. Combination Mek and Jak inhibitor treatment for 
20 hours resulted in the downregulation of both phosphorylated forms of Stat3 (Figure 2-15a). 
When the functional impact of the inhibition of the Mek and Jak pathways was assessed with the 
clonal neurosphere formation assay, we observed that individually, Mek or Jak pathway 
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inhibition did not affect neurosphere formation of the MBNS (Figure 2-15b, c). However, the 
combinatory inhibition of Mek and Jak inhibitors significantly reduced neurosphere formation 
and the size of neurospheres formed (Figure 2-15c, d). Together these data reveal that 
modulation of both phosphorylated forms of Stat3 using a combinatoric treatment of Mek and 
Jak inhibitors inhibits MBNS formation. 
 
Figure 2-15 Combinatory treatment of Jak and Mek inhibitors leads to a synergistic reduction in MBNS self-
renewal and size 
(a) Western blot of MBNS protein lysates after Mek, Jak, and Mek+Jak inhibitor treatment for 3 hours. (b) Clonal 
neurosphere formation assays were carried out in the presence of inhibitors of Mek (10uM U0126), Jak (1uM Jak 
inhibitor 1), or both Mek and Jak (10uM U0126 and 1uM Jak inhibitor 1) for 7 days, with drug supplementation on 
day 3. (c) Significant reduction of NS formation is observed with the combination treatment of Mek and Jak 
inhibitors (p<0.001 by one-way ANOVA with a Bonferroni post test). (d) Combination drug treatment also resulted 
in smaller NS. NS diameters were measured from 60 NS per treatment condition. 
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MBNS self-renewal is, in part, mediated by Stat3, but less significant than the role of Klf4 
As the kinase inhibitors are not specific to Stat3 and likely affecting many other 
pathways, to examine the functional role of Stat3 upregulation in MBNS in a more specific 
manner, we constructed lentiviral vectors encoding two independent shRNAs (Reynolds et al., 
2004) against Stat3 (Table 2). Western blotting validated Stat3 kd at the protein level by day 8 
(d8) post-infection (Figure 2-16a) and time course analysis of Stat3 mRNA expression also 
showed a stable kd throughout day 3 (d3) to day 15 (d15) post-infection. Kd was maintained at 
about 20% of control levels in the Stat3 kd bulk cultures, which are seeded at a density of 2-
3x10
5
 cell/ml (Figure 2-16b). The downstream effect on Stat3 target, Klf4, was observed by day 
8 (d8). However, we also noted that Klf4 mRNA expression rebounded to WT levels by d15 
post-infection. To determine the functional role of Stat3 in MBNS self-renewal, on d3 following 
lentiviral infections, MBNS were plated at clonal density (100 cells/ml) in vitro and we observed 
about a 50% reduction in neurosphere formation compared to the vector control (Figure 2-16c). 
Similar to the shKlf4 MBNS, limiting dilution assays were carried out to determine the frequency 
of self-renewing cells in shStat3 MBNS and extreme limiting dilution analyses (ELDA) showed 
that self-renewing indexes decreased from 1 in 5.1 cells in the control to 1 in 10.5 and 1 in 7.3 in 
the shStat3 #1 and #2 MBNS, respectively (Figure 2-16d). However, the effect on Stat3 kd on 
MBNS self-renewal was less significant than the Klf4 kd. These effects are more apparent when 
the ELDA was carried out by combining the data from limiting dilution assays from both Stat3 
and Klf4 kd MBNS (Table 3). These results show that MBNS self-renewal depends, in part, on 
Stat3, an upstream activator of Klf4.  
 58 
 
 
Figure 2-16 Stat3 kd leads to a reduction in MBNS self-renewal 
(a) Western blot of protein lysates from d8 post-infection shStat3 MBNS with total and pSer Stat3 antibodies 
confirmed Stat3 kd with 2 independent shRNA hairpins. (b) A time course-dependent effect on Stat3 kd and 
downstream target Klf4 was measured by quantitative RT-PCR in d3, d8, and d15 post-infection shStat3 bulk 
cultures. (c) Stat3 kd resulted in significant reduction of self-renewal in the clonal density (100 cell/ml) 6-well NS 
formation assay. The efficiency of NS formation was expressed relative the vector control. (n=4 for shStat3 #1, n=3 
for shStat3 #2; 6 wells quantified per shRNA per experiment; p<0.001 by one-way ANOVA with a Dunnett post 
test). Representative images of wells from the NS formation assay quantitated by ImageJ are shown. (d) A 
clonogenic limiting dilution assay (Tropepe et al. 1999) was carried out and self-renewal indexes of the shStat3 
MBNS were determined by extreme limiting dilution analysis (ELDA) (Hu and Smyth, 2009). P-values are 
determined by tests for pair-wise differences between the vector control and each of the shRNAs by ELDA. 95% 
confidence intervals are indicated by the dotted lines. All values are represented as mean±s.e.m. 
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Table 2. Hairpin sequences of shStat3 
 
Position indicates the first nucleotide position site where the shRNA binds in the target sequence. Scores as 
determined by two rule-based design algorithms, DSIR (http://biodev.extra.cea.fr/DSIR/) and pSicoOligomaker 1.5 
(http://web.mit.edu/jacks-lab/protocols/pSico.html). The predicated efficacy threshold value is set at 90 in DSIR. A 
Oligomaker score of greater than 6 is reported to have ~90% chance of silencing the target (Reynolds et al., 2004). 
 
Table 3. Statistical analyses of extreme limiting dilution analyses (ELDA) of Stat3 and Klf4 kd MBNS self-
renewal 
 
Stem cell frequencies, 95% confidence intervals, and statistical tests for significance between stem cell frequencies 
were determined by the ELDA webtool (http://bioinf.wehi.edu.au/software/elda/). 
Klf4 levels rebound in a Stat3-independent manner in clonally derived shStat3 MBNS 
 
The partial inhibition of MBNS self-renewal in Stat3 kd cells suggested the potential for 
a Stat3-independent, compensatory mechanism for the maintenance of self-renewal in clonal 
cultures. To rule out the possibility that the surviving d8 Stat3 kd MBNS in the clonal 
neurosphere formation assay was not due to loss of expression of the Stat3 hairpins or another 
RNAi escape mechanism, we examined Stat3 expression in shStat3 MBNS that emerged from 
the clonal NS formation assay (Figure 2-17a). Stat3 kd was maintained at levels significantly 
lower than the controls in both the clonally derived shStat3 NS and the higher-density bulk 
cultures at d8 (Figure 2-17b). However, supporting the role for Klf4 in self-renewal as described 
above, we observed Klf4 expression rebounding to levels greater than WT levels in the surviving 
shStat3 NS derived from the clonal density cultures, but remained decreased as a secondary 
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effect of Stat3 kd in the high-density bulk cultures (Figure 2-17b). The clonogenic neurosphere 
assay assesses the cell-intrinsic ability for self-renewal and survival under stringent, clonogenic 
conditions. In contrast, higher-density bulk cultures may contain a heterogeneous population of 
cells, including differentiating cells remaining in NS as a result of cell aggregation that may not 
require Klf4 expression for survival. Furthermore, cell-to-cell contact or secretion of other 
paracrine growth factors by a heterogeneous population of cells may also be involved in 
supporting the growth or self-renewal of cells in the bulk cultures. In fact, in adult hippocampus 
NSC, bFGF alone does not support the mitogenic activity in low density cultures; high density 
cultures are required for the sufficient production of a necessary autocrine/paracrine cofactor 
(Taupin et al., 2000). These results suggest that a Stat3-independent upregulation of Klf4 is 
associated with the maintenance of clonogenic MBNS self-renewal.  
 
Figure 2-17 Klf4 expression rebounds in Stat3-independent manner in clonal density 
(a) Experimental timeline of the Stat3 kd in the MBNS and the distinct clonal and bulk shStat3 cultures obtained for 
analyses. Following antibiotic selection of lentivirally infected MBNS, shStat3 MBNS were assayed for Stat3 
knockdown, self-renewal in clonal density (100 cells/ml) cultures, or passaged for maintenance in bulk culture (2-3 
x 10
5
 cells/ml) on d3 post-infection. (b) Expression analyses of Stat3 and Klf4 in self-renewing NS derived from the 
d8 post-infection shStat3 bulk (2-3 x 10
5
 cells/ml) and clonal density (100 cells/ml) cultures show a significant 
upregulation of Klf4 in the low-density cultures (p<0.001 for shStat3 #1; p<0.0001 for shStat3 #2), while Stat3 kd is 
maintained at significant low levels (p<0.0001). Statistical significance was determined by a one-way ANOVA with 
a Dunnett post test.  
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Stat3 and Klf4 independently regulate the expression of Stat3-target survival genes 
 
As a survival mechanism for cancer cells, Klf4 has been reported to suppress the 
apoptotic response of cancer cells following DNA damage (Ghaleb et al., 2007). Stat3 also has 
known roles in survival by directly regulating the expression of anti-apoptotic target genes 
including survivin (Gritsko et al., 2006), Bcl-x (Catlett-Falcone et al., 1999), Mcl1 (Epling-
Burnette et al., 2001), all of which have been reported to be aberrantly expressed or activated 
and involved in conferring resistance to apoptosis in various tumor types (Ambrosini et al., 1997; 
Hazan-Halevy et al., 2010). When we examined the promoter regions of the Stat3-target survival 
genes, as expected, Genomatix promoter analyses identified Stat3-binding motifs (Figure 2-18a, 
b, c) within the promoter regions of survivin, Bcl-x and Mcl1 (Figure 2-18c, 19, 20). 
Interestingly, we also observed predicted Klf4-binding sites (Figure 2-18b) in close proximity to 
the Stat3-binding sites, further validated by analyzing ChIP-Seq datasets from published studies 
(Figure 2-18c). 
 
Figure 2-18 Binding site motifs of Stat3 and Klf4 and overview of binding sites in the Stat3-target survival 
gene promoters as determined by Genomatix 
(a-b) The binding motifs have been identified by Genomatix by weight matrices containing 375 binding sites for 
Stat3 and 355 binding sites for Klf4 from ChIP-Seq data from Chen et al. 2008. (c) Schematic of the survivin, Bcl-x, 
and Mcl1 promoters with locations of predicted Stat3 and Klf4-binding sites. The binding positions indicate the 
position of anchor sequence (center position) of the predicted binding sites in relation to the transcriptional start site 
(+1). Analyses of ChIP-Seq data by TRANSFAC showed Klf4 binding to the survival gene promoters in ES cells. 
 62 
 
 
 
 
Figure 2-19 Mcl1 and survivin promoter analyses identify predicted Klf4 binding sites in close proximity to 
predicted Stat3-binding sites. 
Genomic sequence of promoters of Stat3-target survival genes survivin and Mcl1 and predicted Stat3 (blue) and 
Klf4 (red)-binding sites by MatInspector (Genomatix Software Suite). Analyses of ChIP-Seq data (from Chen et al. 
2008) by TRANSFAC showed Klf4 binding to the survival gene promoters in ES cells. Binding fragments are 
indicated by the pink blocks. 
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Figure 2-20 Bcl-x promoter analysis identifies predicted Klf4-binding sites in close proximity to predicted 
Stat3 binding sites. 
Genomic sequence of promoters of Stat3-target survival gene Bcl-x and Stat3 (blue) and Klf4 (red) binding sites 
predicted by MatInspector (Genomatix Software Suite). Two promoter regions are identified for Bcl-x, as indicated 
by the boxed regions. Analyses of ChIP-Seq data (from Chen et al. 2008) by TRANSFAC showed Klf4 binding to 
the Bcl-x gene promoters in ES cells. Binding fragments are indicated by the pink blocks. 
Therefore, we next asked if Stat3 and Klf4 kd affected expression of the survival genes in 
the MBNS. When Stat3 or Klf4 were individually knocked down at d3 post-infection, the 
expression of Bcl-x and Mcl1 remained at levels unchanged relative to the control, although 
survivin expression was reduced in the Klf4 kd (Figure 2-21a). By d8 post-infection in shStat3 
bulk cultures, when Stat3 and Klf4 levels were both reduced to 20% and 40% of control levels, 
 64 
respectively (Figure 2-17b), coordinate downregulation of Bcl-x and Mcl1 expression was 
observed (Figure 2-21b). However, in the d8 shStat3 clonal cultures, when Klf4 levels rebounded 
(Figure 2-17b), survival gene expression was maintained at WT levels, suggesting that Stat3 and 
Klf4 can compensate for each other in maintaining the expression of the target survival genes. 
The observations in the bulk culture may also reflect the heterogeneity in this high cell-density 
culture, as suggested by the cells present in the bulk culture with both Stat3 and Klf4 levels 
reduced, which may be representing non-stem cells that do not require Klf4 and target survival 
genes for their self-renewal or are dependent on other mechanisms or pathways for survival. 
 
 
 
Figure 2-21 Stat3 or Klf4 expression is sufficient for the maintenance of Stat3-target survival gene expression 
(a) Independent Stat3 and Klf4 kd does not affect survival gene expression in MBNS, as measured by quantitative 
RT-PCR in the d3 post-infection shKlf4 and shStat3 MBNS bulk cultures. The expression of Bcl-x, and Mcl1 are not 
affected by the kd of Klf4 or Stat3. Survivin expression is reduced in the Klf4 kd MBNS (P<0.01). (b) In d8 post-
infection shStat3 MBNS, a compensatory upregulation of Klf4 in the clonal cultures is associated with the 
maintenance of survival gene expression. In the d8 shStat3 bulk cultures, when both Stat3 and Klf4 levels are 
reduced, there is a significant reduction in the expression of Bcl-x and Mcl1 (p<0.0001). Statistical analyses were 
carried out by one-way ANOVA with a Dunnett post test. Expression values are normalized to the vector control 
and represented as meansem. 
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BCL-X and CD133 expression in human medulloblastoma is associated with poor survival 
 
When the expression of the STAT3 and KLF4 target survival genes was further analyzed 
in a human medulloblastoma expression dataset (Kool et al., 2012), significant upregulation of 
BCL-X, but not MCL1 and BIRC5 (Survivin) was observed in the Group 3 tumors, which have 
the worst overall survival probability (Northcott et al., 2011b) (Figure 2-22, 23). Furthermore, 
expression of PROM1 (CD133), a NSC marker enriched in the MBNS (Figure 2-1) was also 
elevated in Group 3 tumors (Figure 2-23), which have modeled by the ex vivo transformation of 
CD133-enriched CbSC (Pei et al., 2012), suggesting the potential utility for NSC and survival 
gene markers as prognostic indicators. In conclusion, by asking about plasticity mechanisms 
within the Ptch1
LacZ/+
;Trp53
-/-
 MBNS, this led us to the identification of Klf4, a reprogramming 
factor, as a gene also crucial for the clonogenic self-renewal of the MBNS. During the 
clonogenic self-renewal of MBNS, Klf4 was upregulated in a Stat3-independent manner and this 
was further associated with the expression of survival genes. 
 
 
Figure 2-22 BCL-X and PROM1 expression is associated with human medulloblastomas with the poorest 
prognosis 
Expression analyses of BCL-X (BCL2L1) and PROM1 (CD133) in the human medulloblastomas from the Northcott 
et al. (2011) dataset indicate significant upregulation of these genes in Group 3, the class with the worst overall 
median survival. All values are represented as mean±s.e.m. 
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Figure 2-23 BCL-X and CD133 are elevated in Group 3 human tumors 
BCL2L1 (BCL-X) expression is significantly higher in Group 3 tumors compared to WNT (p<0.001), SHH 
(p<0.0001) and Group 4 (p<0.0001). PROM1 (CD133) is also elevated in Group 3 compared to SHH (p<0.01) and 
Group 4 (p<0.001) tumors. The expression of BIRC5 (Survivin), MCL1 and GAPDH, however, are not significantly 
(n.s.) different between the tumor classes. Expression values are plotted as mean±s.e.m and statistical analyses was 
carried out by one-way ANOVA with a Bonferroni post test. The number of human tumors analyzed are as follows 
WNT=8, SHH=33, Group 3=27; Group 4=35. 
 67 
 
Discussion 
 
 
 While efforts to model different subtypes of human medulloblastoma have led to several 
targeted therapies (Lau et al., 2012), the molecular and genetic pathways involved in relapsing 
tumors or tumor stem cells are not well understood. In particular, Ptch1
LacZ/+
;Trp53
-/-
 mouse 
medulloblastomas provide a tractable model for studying the potential role of self-renewing, 
stem-like cells in these tumors. Ptch1
LacZ/+
tumors have been characterized as granule neuron 
progenitor (GCP)-driven tumors, which develop as a focal mass and do not exhibit properties of 
self-renewal in neurosphere culture conditions (C. Lin thesis). In contrast, Ptch1
LacZ/+
;Trp53
-/-
 
tumors are more diffuse and exhibit stem cells characteristics, including high expression of NSC 
markers such as CD15 and CD184, in comparison to the Ptch1
LacZ/+
 tumors, and exhibit self-
renewing neurosphere formation. These Ptch1
LacZ/+
;Trp53
-/-
  MBNS are enriched in stem cell 
marker expression and are able to initiate tumors upon transplantation in vivo. As shown in this 
chapter, we also observed that these MBNS also displayed plasticity and growth in ES cell 
culture conditions as self-renewing, AP
+
 colonies, despite the presence of differentiating factors 
in serum. We further discovered that Klf4, a reprogramming factor, was crucial for 
Ptch1
LacZ/+
;Trp53
-/-
 MBNS plasticity and self-renewal and Klf4 expression was upregulated in a 
LIF/Stat3-independent manner during clonogenic growth. Our work suggests that the 
Ptch1
LacZ/+
;Trp53
-/-
 MBNS are able to utilize endogenously activated components of the 
pluripotency transcription factor network to sustain expression of genes important for growth in 
clonal conditions in both ES culture conditions in the in vitro reprogramming assay and in 
neurosphere culture conditions. 
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Tumor-initiating, self-renewing Ptch1
LacZ/+
;Trp53
-/-
 medulloblastoma cells  
Ptch1
LacZ/+
;Trp53
-/-
 tumors are able to be propagated as self-renewing neurospheres, 
display enriched expression of stem cell markers including CD15, CD133 (Figure 1-1), nestin, 
Sox2 (C. Lin thesis) and are capable of secondary tumor initiation when transplanted into the 
cerebella of immunocompromised mice. Serum-free neurosphere culture with growth factors 
EGF and bFGF was initially developed for the isolation of multipotent NSC (Reynolds et al., 
1992), but has been extensively utilized for the enrichment of human brain tumor stem cells in 
vitro (Singh et al., 2003; Hemmati et al., 2003; Galli et al., 2004; Dirks, 2008). Neurosphere 
cultures have been shown to select for cells with tumor-initiating ability that reliably maintain 
the characteristics of the primary tumor (Lee et al., 2006), whereas non-sphere-forming cells 
were unable to initiate tumor-formation in vivo (Yuan et al., 2004). Postnatal CbSC have also 
been isolated and characterized as a Math1-negative, bFGF-responsive, CD133-positive 
population, which grow as self-renewing, Sox2 and nestin-positive neurospheres in vitro and 
exhibit multipotent differentiation in vitro and in vivo (Lee et al., 2005). This is in contrast to 
Math1-positive GCP of the cerebellum, which cannot proliferate in response to bFGF (Lee et al., 
2005), consistent with the observation that bFGF inhibits GCP proliferation and induces 
differentiation in Ptch1
LacZ/+
tumor cells (Fogarty et al., 2007). The presence of bFGF-responsive 
Ptch1
LacZ/+
;Trp53
-/-
 cerebellar stem-like cells in the tumors and in 3 week old animals (C. Lin 
thesis), suggests an aberrantly persistent population of CbSC. Alternatively, the possibility of 
GCPs to develop a resistance to bFGF-induced differentiation or acquire a more dedifferentiated 
state cannot be excluded. To differentiate between these two possibilities, lineage-tracing studies 
following the prospectively labeled CbSC and GCP populations would be necessary.  
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Although the aforementioned characteristics of the Ptch1
LacZ/+
;Trp53
-/-
 MBNS is 
suggestive of the enrichment of a tumor-propagating cell from the primary tumors with 
neurosphere culture, the possibility of clonal selection of cells or tissue culture-induced changes 
promoting increased proliferation and survival must be considered. To ascertain the role of bona 
fide cancer stem cells in these tumors, prospective isolation of an endogenous cell population 
with a stem cell marker that can isolate the self-renewal and tumor-initiating activity is necessary 
and will be further addressed in Chapter 3. In the absence of a validated prospective marker, in 
acute myeloid leukemia (AML), for example, where CSC were first identified, injections of ten-
fold limiting dilution series of unfractionated AML cells were carried out for the quantification 
of AML-initiating cells (Bonnet and Dick, 1997). To further bolster the role of stem cells in the 
Ptch1
LacZ/+
;Trp53
-/-
 medulloblastomas, neurosphere differentiation assays to determine 
multipotency and quantitative serial transplantation assays will also need to be carried out. 
Nonetheless, it is important to understand the role of these Ptch1
LacZ/+
;Trp53
-/-
 MBNS, as they 
are responsive to culture conditions validated for the enrichment of NSC and other brain tumor 
stem cells (Dirks, 2008) and demonstrate robust self-renewal and tumor-initiating capability. 
 
Phenotypic conversion of MBNS 
Phenotypic conversion of MBNS in an in vitro reprogramming assay suggests that 
pathways shared with the pluripotency network of ES cells can be utilized as a plasticity 
mechanism by MBNS. The reprogramming of somatic cells to pluripotency involves directed 
dedifferentiation through ectopic expression of the transcription factors, Oct4, Sox2, c-myc, and 
Klf4 (Takahashi and Yamanaka, 2006). These same reprogramming genes are normally 
expressed in CD133-enriched WT cerebellar cells and neurospheres (Po et al., 2010), suggesting 
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that the pluripotency networks are mostly conserved in NSC. However, our control experiments 
with developmental CbSC did not provide evidence for colony formation in the in vitro 
reprogramming assay when dissociated neurosphere cells were plated in ES culture conditions. 
While cortical NSC require exogenous Oct4 expression for reprogramming (Kim et al., 2009), 
the MBNS showed endogenous activity and AP
+
 colony formation and growth without added 
factors. Our data suggest that the requirement for exogenous factors may be relieved by 
tumorigenesis. In human cancers, a c-myc centered transcriptional network contributes to the ES-
like signatures observed in cancer, rather than the core ES module defining ES cells (Kim et al., 
2010), challenging the notion of the dedifferentiation of cancer cells to an ES-like state. 
Nonetheless, the molecular underpinnings of the MBNS with ES-like gene signatures led us to 
predict that these cells may exhibit characteristics of plasticity and respond in ES culture 
conditions. In fact, histological analyses of the AP
+
 MBNS-derived teratomas suggest an 
increased diversity in the cell types generated in comparison to the parental MBNS-derived 
tumors which are characterized by a more differentiated cell type, although further marker 
analysis is required to definitively determine the distinct neural cell types present. It should be 
also noted that the control Ptch1
LacZ/+
;Trp53
-/-
 ES cell-derived teratomas only consisted of 
neuroectodermal cells and did not exhibit the formation of all three germ layers, which may be 
due to the mutant Ptch1
LacZ/+
genotype biasing the differentiation into neural lineages in the 
teratoma assay. The role of Shh signaling in neural development is well established and neural 
tube defects and overgrowth in the hindbrain, spinal cord and headfold are observed in Ptch1 
null embryos (Goodrich et al., 1997).  
Cancer genomes have previously been reported to be epigenetically reprogrammed to 
pluripotency by nuclear transplantation (Li et al., 2003; Hochedlinger et al., 2004) and through 
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induction of ectopic pluripotency factors (Lang et al., 2012). The in vitro reprogramming assay 
may be selecting for those MBNS with tumor-associated epigenetic changes that allow the cells 
to modulate pluripotency transcription factors and respond to ES culture conditions. Methylation 
analyses of the regulatory regions of pluripotency genes showed that Oct4 and Nanog remained 
methylated in the AP
+
 MBNS and c-myc and Stat3 remained hypomethylated. However, a 
significant reduction in DNA methylation was observed at the 5’ regulatory regions of Klf4 (and 
Sox2 to a lesser degree) between the MBNS and AP
+
 MBNS, which led us to ask if Klf4 may be 
involved modulating the phenotypic plasticity. We have not, however, quantitatively examined if 
the differential CpG methylation at the 5’ regulatory regions directly reflects a modulation of 
gene expression. Nonetheless, Klf4 has a known role for preventing the differentiation of ES 
cells in the absence of LIF (Zhang et al., 2010) and Klf4 expression is required for epiblast stem 
cells (EpiSC) with restricted potency to attain the ground state pluripotency of ES cells (Guo et 
al., 2009). Consistent with this, Klf4 kd resulted in reduction of AP
+
 colony formation in ES 
culture conditions. Furthermore, Klf4 was also functionally important in the clonal self-renewal 
of MBNS. It is unknown, however, if the conversion of MBNS in the reprogramming assay is 
occurring due to a culture-induced epigenetic adaptation or through the selection of a pre-
existing population of cells in the primary tumor. For example, the MBNS culture may contain a 
more primitive NSC, which has been shown to be present as a LIF-dependent population of cells 
in the neuroectoderm before the formation of the neural tube (Hitoshi et al., 2004).  
 The role of the Trp53 mutation during the phenotypic conversion of the MBNS must also 
be considered and may be exhibiting a two-fold effect. Trp53 is a potent barrier to 
reprogramming, as Trp53 inhibition accelerates the generation of dedifferentiated stem cells 
(Utikal et al., 2009; Marión et al., 2009; Hong et al., 2009; Kawamura et al., 2009; Li et al., 
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2009). In addition, p53 loss also increases the adult stem cell pool in various tissue systems 
including the CNS (Meletis et al., 2006). Therefore, the acquisition of developmental plasticity 
and an increase in the stem cell pool by the inactivation of Trp53 may render the 
Ptch1
LacZ/+
;Trp53
-/-
 tumor cells more susceptible to tumor-associated reprogramming (Spike and 
Wahl, 2011). 
 
Oncogenic role of Klf4 in MBNS 
 Klf4 is a zinc finger transcription factor, which has known roles in a wide range of 
functions including the regulation of cell proliferation, differentiation and apoptosis. Klf4 is 
highly expressed in the intestine, where it was first identified, and in skin epithelial cells (Shields 
et al., 1996). Klf4 has been shown to function as both an inhibitor of cell proliferation and 
inducer of differentiation. In a colon cancer cell line, Klf4 negatively regulates cell proliferation 
by inhibition of cell cycle progression at G1/S (Chen et al., 2001). The crucial role of Klf4 in the 
induction of differentiation is highlighted in the Klf4 knockout mice, which die perinatally due to 
a defective skin barrier function and dehydration caused by aberrant differentiation of the skin 
(Segre et al., 1999) and colon epithelia (Katz et al., 2002). In human tumors, Klf4 has been 
reported to display opposing functions, as either a tumor suppressor or an oncogene depending 
on the context and tumor type. While Klf4 is a tumor suppressor gene in colon and gastric 
cancer, it has oncogenic roles in other cancer cancers such as squamous cell carcinoma and 
breast cancers (Rowland and Peeper, 2006).  
The role of Klf4 in medulloblastomas has not been studied extensively, but it has been 
reported that Klf4 expression is silenced by genetic events such as chromosomal deletions and 
promoter methylation in human medulloblastomas (Nakahara et al., 2010). This study also 
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showed that overexpression of Klf4 in medulloblastoma cells lines led to growth suppression 
both in vitro and in vivo, suggesting the role of Klf4 as a tumor suppressor. Although, one must 
consider that serum-cultured cell medulloblastoma lines were utilized. However, other studies 
show an association between tumorigenesis and upregulation of Klf4 expression. In Ptch1
+/-
 
tumors, Klf4 expression was observed to be elevated in comparison to the pre-neoplastic lesions 
and GCPs (Oliver et al., 2005). And as a STAT3-target, high KLF4 expression has also been 
observed as part of the genetic signature of human tumors with activated Stat3 signaling 
(Alvarez et al., 2005). Our results with RNAi and small molecule inhibitors show that in the 
Ptch1
LacZ/+
;Trp53
-/-
 MBNS, Klf4 expression is also, in part, regulated by Stat3 and Klf4 
expression is specifically upregulated in the self-renewing MBNS. Recently, Klf4 has been 
shown to be functionally important in the self-renewal of ES cells and the reprogramming of 
somatic cells to iPS cells, as one of the original four reprogramming factors (Takahashi and 
Yamanaka, 2006). As a reprogramming factor, Klf4 was characterized to function as a key 
component of the transcriptional network of pluripotency in ES cells, as an upstream regulator of 
Oct4, Sox2, Nanog, and c-myc (Kim et al., 2008a). Specifically, in the absence of LIF, Klf4 
expression prevents ES cell differentiation by regulating Nanog (Li et al., 2005; Zhang et al., 
2010). Klf4 is also expressed in normal NSC and CbSC (Po et al., 2010; Kim et al., 2009), 
although the function has not been directly addressed. In a study that examined the role of Klf4 in 
cortical NSC, high levels of Klf4 expression was observed in the NSC but was decreased in 
differentiated neurons and astrocytes (Qin et al., 2011), suggesting its potential role in the 
maintenance of stem cells. However, overexpression of Klf4 resulted in the reduction of 
proliferation and self-renewal and led to impairment in neural differentiation (Qin et al., 2011). 
While this shows that precise levels of Klf4 are critical for the regulation of normal neurogenesis, 
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the role of endogenously expressed Klf4 in NSC still remains unclear. The functional role of Klf4 
in the cerebella or cerebellar stem cells, specifically, has also not yet been described. 
In Ptch1
LacZ/+
;Trp53
-/-
 MBNS, our results suggest that Klf4 functions to maintain self-
renewal through both Stat3-dependent and independent mechanisms. The compensatory Stat3-
independent expression of Klf4 during clonogenic neurosphere formation supports an oncogenic 
function with its involvement in the maintenance of MBNS self-renewal. In the context of CSC, 
a study in breast cancers has shown that Klf4 kd results in a reduction in the frequency, self-
renewal, and in vivo tumorigenicity of the breast CSC population (Yu et al., 2011). Also in breast 
cancer, the upregulation of Klf4 via miR-29 repression contributes to the expansion of 
CD44
+
/CK5
+
 stem-like tumor-initiating cells and knockdown of Klf4 leads to the reduction of the 
frequency of these cells (Cittelly et al., 2013), further providing evidence for an oncogenic role 
of Klf4 in certain tumor stem cells. 
 
Role of constitutive activation of Stat3 in MBNS self-renewal 
 Several lines of evidence show aberrantly activated STAT3 signaling to be important in 
human tumors including medulloblastomas (Yu and Jove, 2004). Tumor-specific activation of 
pSer727 STAT3 is observed in primary human medulloblastomas (Yang et al., 2008a) and the 
MBNS also showed elevated Stat3 expression that was associated with robust pSer727 
activation. The elevated expression of Stat3, which was also seen in WT CbSC, suggests that 
overexpression of Stat3 in MBNS may be reflective of a developmental origin of these tumors. 
Abundant expression of Stat3 has, in fact, been observed in cerebellar white matter at P3 and P10 
in the postnatal rat brain (Gautron et al., 2006). Recent studies have demonstrated that small 
molecule drugs can inhibit the proliferation of the Daoy medulloblastoma cell line via inhibition 
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of Stat3 and Akt pathways (Yang et al., 2008a; 2010b). Although it must be noted that Daoy 
cells are also propagated as adherent serum-adapted cultures, which have been described to alter 
the characteristics of the original tumors (Lee et al., 2006; Sasai et al., 2006), while we have 
specifically examined the function of Stat3 activation in the self-renewing MBNS. 
The effect of Stat3 pathway inhibitors on MBNS shed some light on the differential 
function of the two post-translational modifications of Stat3; pTyr705 Stat3 is robustly inhibited 
by Jak inhibition and Mek inhibition led to a partial, but consistent decrease in pSer727 Stat3. 
Mek inhibition may be reducing pSer Stat3 by blocking the activity of ERK2, a downstream 
kinase shown to phosphorylate Stat3 at Ser727 in different contexts (Chung et al., 1997; Turkson 
et al., 1999). However, pSer727 Stat3 was only partially inhibited and this is likely due to the 
contribution of other tumor-related MAPK pathway kinases such as JNK, p38, and PKC 
(Roberts and Der, 2007). The treatment of MBNS with Jak and Mek inhibitors suggest that these 
pathways independently are not crucial for the maintenance of MBNS self-renewal. The lack of 
an effect on the clonal self-renewal with the Jak inhibitor despite the robust inhibition of 
pTyr705 Stat3, the main transcriptional activation signal, suggests that the activation of Stat3 
signaling is not crucial for the maintenance of MBNS self-renewal. The inhibition of Mek 
signaling, which is involved a multitude of functions including transcriptional regulation, 
proliferation, differentiation limits the use of the Mek inhibitor to query a Stat3-specific effect. 
However, the robust inhibition of Mek signaling, as measured by the reduction of MAPK 
phosphorylation shows that Mek inhibition alone also does not significantly affect MBNS self-
renewal.  
The combination treatment of Jak and Mek inhibitors results in a significant reduction of 
neurosphere formation, suggesting that the concurrent inhibition of both pathways is important 
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for the effective reduction in MBNS self-renewal. Similarly, a synergistic effect of Stat3 and 
Mek pathway reduction has been observed to inhibit the growth of multiple myeloma cells 
(Nelson et al., 2008). However, the limitations of utilizing kinase inhibitors must be taken into 
consideration when interpreting the specific roles of Stat3 and Klf4 in the MBNS. While the 
activation of pStat3 is a major role of Jak kinases, they are also involved in a variety of other 
functions such as the phosphorylation and activation of other growth factor and cytokine 
receptors, including the granulocyte macrophage colony-stimulating factor (GM-CSF) and type I 
interferon receptor (Rane and Reddy, 2000) that may lead to a Stat3-independent effect. 
Furthermore, as mentioned above Mek signaling is involved in a variety of cellular processes. 
Nonetheless, further examination of the mechanism involved in the inhibition of MBNS self-
renewal by the combination Jak and Mek inhibitors may reveal novel effectors of survival 
signaling in the MBNS. 
 While Stat3 expression may not be necessary for the maintenance of MBNS self-renewal 
and survival, sustained Stat3 signaling may be aiding the stabilization of the transcriptional 
circuitry for pluripotency and survival in the MBNS. Stat3 functions in cooperation with the 
pluripotency factor Oct4 to sustain ES cell self-renewal by inducing Klf4 expression (Hall et al., 
2009). Furthermore, Stat3 synergizes with Klf4 and Nanog to reset the transcriptional program to 
overcome the barrier for reprogramming epiblast stem cells (EpiSC) to pluripotency (Yang et al., 
2010b). The role of pTyr705 Stat3 in direct transcriptional regulation of target genes, including 
Klf4 and c-myc, is well established. In the MBNS, pTyr705 Stat3 inhibition by Jak kinase 
inhibition reduces the expression of Socs3, Stat3 and secondarily, the expression of Klf4. While 
pSer727 Stat3 in mice has been reported to be required for maximal transcriptional activity, its 
role in DNA binding and gene regulation is not well established (Decker and Kovarik, 2000). 
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However, the human homolog pSer STAT3 has been shown to directly bind DNA and activate 
the transcription of antiapoptotic genes such as survivin, Mcl1, Bcl-x in CLL in a pTyr705 
STAT3-independent manner (Hazan-Halevy et al., 2010). This may reflect a conserved 
mechanism for regulating survival genes in MBNS, through the collaborative involvement with 
Klf4. 
 
Role of Stat3-independent regulation of Klf4 during clonogenic self-renewal 
Despite the MBNS exhibiting significantly elevated levels of Stat3 mRNA expression 
and phospho-Stat3 activation, Stat3 kd by RNAi and kinase inhibitors led to a moderate decrease 
in the formation of self-renewing neurospheres and the Stat3 kd was not as functionally 
significant as the role of Klf4, especially apparent in the limiting dilution neurosphere formation 
assay. We have observed two discreet phenomena of Klf4 regulation that occur in a cell density-
dependent manner. The upregulation of Klf4 expression in MBNS with sustained Stat3 kd 
suggests that MBNS can, in part, escape and self-renew if Klf4 expression is selectively 
upregulated during clonogenic growth. At higher cell densities, the compensatory mechanism of 
Klf4 expression does not take effect, suggesting that there may be cell non-autonomous signals at 
higher cell densities, which relieve the necessity for Klf4 expression. This leads us to hypothesize 
that gene expression networks may be relaxed if not necessary, but under environmental 
challenges such as clonal growth, the consolidation of gene expression necessary for MBNS 
survival occurs, either by the selection of cells expressing Klf4 or by inducing cells to rapidly 
upregulate Klf4. Additionally, this suggests that the major mode of Klf4 regulation during MBNS 
clonogenic growth can occur through a mechanism independent of the canonical LIF/STAT3 
pathway, for which Klf4 is direct downstream target.  
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While the partial effect of the Stat3 kd on MBNS self-renewal may be attributable to the 
downregulation of Klf4 downstream of Stat3, the inhibition of Stat3 signaling alone is not 
sufficient because Stat3-independent activators of Klf4 can compensate. These activating signals 
of Klf4 remain to be determined, but Shh signaling may be involved in a Stat3-independent 
mechanism for Klf4 activation via the network of pluripotency factors, as Shh has been reported 
to be upstream of transcriptional activation of Klf4 (Sengupta et al., 2007; Moon et al., 2011). 
Furthermore, the MBNS we describe are driven by loss of the Ptch1 tumor suppressor that 
governs Shh signaling. Overexpression of Gli1, a downstream activator of Shh signaling, has 
also been shown to enhance clonogenic NSC, which was associated with the concurrent 
upregulation of pluripotency genes including Nanog, Sox2, Klf4, and CD133 (Stecca and Ruiz i 
Altaba, 2009), of which Nanog and Sox2 have been shown to be directly regulated by Gli1/2 
binding (Po et al., 2010; Takanaga et al., 2009). It will be important to further elucidate the 
multiple modes of activation of Klf4 expression for the effective inhibition of MBNS survival 
and self-renewal for therapeutic applications. In conclusion, our work suggests that 
Ptch1
LacZ/+
;Trp53
-/-
 MBNS are able to utilize the endogenously active components of the 
pluripotency transcription factor network, specifically Klf4, which is functioning partially via the 
Stat3 signaling pathway, as a factor critical for both MBNS plasticity and clonal self-renewal. 
 
Methods 
 
Neurosphere culture of MBNS line  
A primary Ptch1
LacZ/+
;Trp53
-/-
 medulloblastoma was isolated, minced with razor blades and 
homogenized in Accutase (Chemicon) and was maintained in suspension culture as neurospheres 
in DMEM:F12 containing B27 Supplement (Invitrogen), 20ng/ml bFGF (Invitrogen), 20ng/ml 
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EGF (Invitrogen), and 100U/ml penicillin/streptomycin (Invitrogen) by weekly serial passaging. 
Neurosphere cultures were passaged by dissociation and trituration with Accutase, 
centrifugation, and followed by resuspension of the cells in fresh NS media. For isolation of 
CbSC, postnatal d5 or d7
 
cerebella were dissected, mechanically dissociated and homogenized 
with Accutase (Chemicon) and cultured in neurosphere media. After 7 days of culture, primary 
neurospheres were dissociated and plated in the in vitro reprogramming assay.  
 
Flow cytometry for cell surface marker expression analyses 
A primary Ptch1
LacZ/+
;Trp53
-/-
 medulloblastoma and neurosphere culture-enriched MBNS line 
was isolated and dissociated as described above and resuspended in Phosphate-buffered saline 
(PBS) with 2mM ETDA and 0.5% BSA. The samples were incubated with PE-conjugated CD15 
(R&D Systems), PE-conjugated CD133/Prominin (Miltenyi), or anti-mouse isotype control 
antibodies for 30 minutes, washed with PBS, then analyzed on the BD LSRII (BD Biosciences). 
Analyses for PE staining were carried out on FlowJo software (Tree Star).  
 
Intracerebellar transplantation assays  
4-6 week old NCr nude (CrTac:NCr-Foxn1
nu
) mice were anesthetized with ketamine/xylazine 
and placed into a stereotaxic frame (Stoelting). A 1 cm incision was made in the scalp and a hole 
was drilled approximately 1mm lateral and 3mm posterior to lambda. 10000, 30000 or 100,000 
cells in 2ul of PBS were drawn into a glass needle and injected into the cerebellum 3mm below 
the surface using a PicoPump (World Precision Instruments). Animals were monitored for the 
development disease symptoms on a daily basis. Mice were maintained in pathogen-free 
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conditions at Boston Children’s Hospital and procedures were performed following approval by 
the Institutional Animal Care and Use Committee (IACUC). 
 
In vitro assay for reprogramming 
For the in vitro reprogramming experiments, 3000 MBNS or CbSC were plated per well of a 6-
well plate on irradiated mouse embryonic fibroblasts (MEF) in Dulbecco’s Modified Eagle 
Medium (DMEM) (Invitrogen) containing 15% FCS (Millipore), 2mM L-Glutamine 
(Invitrogen), 100U/ml penicillin/streptomycin, 100uM non-essential amino acids (Invitrogen) 
and 1000U/ml leukemia inhibitory factor (Millipore). Six days post-plating, cells were fixed with 
2% paraformaldehyde (Electron Microscopy Sciences) and stained for alkaline phosphatase 
(Vector Laboratories). The frequency of AP-positive ES-like colony formation was determined 
by counting the homogenously AP-positive colonies. Stable AP
+
 MBNS subclones were 
maintained in standard ES cell culture conditions. Plating efficiency assays to determine LIF-
dependency were performed by plating 3000 AP
+
 MBNS per well of a 6-well plate in technical 
triplicates, on gelatin or MEF in ES media with or without LIF. Six days post-plating, colonies 
were fixed, stained for AP, and quantified by ImageJ. Briefly, images of wells were 
photographed, converted to a grayscale image and thresholded to highlight the colonies, which 
were counted by the “measure nuclei” macro under the analyze particles function menu.  
 
Teratoma assays 
The flanks of 4-6 week of NCr nude (CrTac:NCr-Foxn1
nu
) mice were subcutaneously injected 
with 10
6
 Ptch1
LacZ/+
;Trp53
-/-
 ES cells (n=3), MBNS (n=5), and AP
+
 MBNS (n=5) resuspended in 
100ul of PBS. Animals were monitored daily for the development disease symptoms, sacrificed 
 81 
3 week post-injection and tumors were dissected and embedded in OCT (Tissue-Tek) for 
cryosectioning for H&E staining for histological analyses. 
 
Bisulfite-based mass spectrometry methylation analyses 
Genomic DNA (gDNA) from the parental MBNS and three AP
+
 MBNS subclone lines were 
isolated with the AllPrep DNA/RNA kit (Qiagen). The MassArray EpiTYPER platform 
(Sequenom, San Diego, CA, USA) was utilized for quantitative analyses of CpG methylation at 
promoter regions and 5’ regulatory regions ~2kb upstream of the TSS for pluripotency genes 
Oct4, Nanog, Klf4, Sox2 and Stat3. Briefly, sodium bisulfite-treated gDNA is PCR-amplified 
with gene-specific primers and followed by in vitro RNA transcription and base-specific 
cleavage. Cleavage products are subsequently analyzed by MALDI-TOF mass spectrometry to 
distinguish between the methylated and unmethylated gDNA. 
 
Gel-based and Quantitative RT-PCR 
Total RNA (1ug) isolated from WT adult cerebella, Ptch1
LacZ/+
;Trp53
-/-
  primary tumors, WT 
and Ptch1
LacZ/+
;Trp53
-/-
 ES cells, WT P7 CbSC, and Ptch1
LacZ/+
;Trp53
-/-
 MBNS lines with the 
RNeasy Kit (Qiagen) was used for cDNA synthesis with the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). Gel-based RT-PCR was carried out by amplifying Oct4 
and Nanog for 31 cycles, Sox2 and Klf4 for 28 cycles, NuBP for 26 cycles and Gapdh for 23 
cycles. Quantitative RT-PCR was carried out in technical triplicates using the SYBR Green PCR 
Master Mix (Applied Biosystems) using cDNA dilutions determined by prior primer 
optimization experiments. Stat3, Socs3, Klf4, survivin, Bcl-x and Mcl1 expression was 
normalized to GAPDH and changes in gene expression were determined by the ddCT method 
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and represented as expression levels relative to the WT cerebella control, vehicle-treated or 
vector control.   
 
Primers: 
Gapdh: 5' GTTGTCTCCTGCGACTTCA 3’; 5’ TGGTCCAGGGTTTCTTACTC 3’  
STAT3: 5’ TGAGAGTCAAGACTGGGCATA 3’; 5’ ACTCTTGCAGGAATCGGCTA 3’ 
Socs3: 5’ GTTCCTGGATCAGTATGATGC 3’; 5’ CGCTTGTCAAAGGTATTGTCC 3’ 
Klf4: 5’ CCCGGCGGGAAGGGAGAAGA 3’; 5’ GGCCGGGAAGTGGGGGAAGT 3’ 
survivin: 5’ CTACCGAGAACGAGCCTGAT 3’; 5’ GGGAGTGCTTTCTATGCTCCT 3’ 
Bcl-x: 5’ GGTGAGTCGGATTCAAGTT 3’; 5’ TGTTCCCGTAGAGATCCACA 3’ 
Mcl1: 5’ GTAAGGACGAAACGGGACTG 3’; 5’ CGCCTTCTAGGTCCTGTACG 3’ 
  
Western Blot Analyses 
MBNS grown in suspension culture were harvested and centrifuged for protein isolation. For 
isolation of protein lysates from adherent ES cells or AP
+
 MBNS grown in ES conditions, MEFs 
were removed by spot-plating on gelatin-coated plates. Cell pellets were lysed in RIPA buffer 
(Upstate) containing phosphatase and protease inhibitors (Pierce) on ice for 30 minutes, with 
vortexing every 10 minutes. After determination of protein concentration by the Dc-Protein 
Assay (Bio-Rad), 30ug of protein was fractionated on a 8% polyacrylamide gel, transferred to 
nitrocellulose membranes and probed with rabbit anti-pSer727 Stat3 (1:10,000, gift from 
D.Frank (Kim et al., 2008a)), rabbit anti-pTyr705 Stat3 (1:10,000, Cell Signaling), rabbit anti-
Stat3 (1:10,000, Santa Cruz), rabbit anti-pErk1/2 (1:10,000, Cell Signaling), mouse anti-actin 
(1:5000, Abcam). Anti-mouse and rabbit HRP-conjugated secondary antibodies (1:10,000, 
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Jackson ImmunoResearch) were incubated on the blots and detected with the Western Lightning 
ECL Reagent (Perkin Elmer).  
 
Pathway inhibitor treatment of MBNS 
Dissociated MBNS were treated with 10uM PI3K inhibitor LY294002 (Cell Signaling), 10uM 
Mek1/2 inhibitor U0126 (Cell Signaling), 250nM mTOR inhibitor Rapamycin (Gift from D. 
Sabatini), and 1uM Jak inhibitor (Calbiochem), or combination Mek and Jak inhibitor. Treated 
MBNS were harvested for protein and RNA isolation or plated in the neurosphere self-renewal 
assay (see below) with additional inhibitor media supplementation 4 days post-plating. 
Neurosphere formation and size was quantified 7 days post-plating.  
 
Generation of shRNA and lentiviral vectors 
shRNA against Stat3 and Klf4 were generated with two rule-based shRNA design software, 
DSIR (http://biodev.extra.cea.fr/DSIR/) and pSicoOligomaker 1.5 (http://web.mit.edu/jacks-
lab/protocols/pSico.html). Oligos were ligated into a pSicoR vector modified from the original 
vector (Ventura et al., 2004) to express the puromycin resistance cassette under the control of the 
Ubiquitin promoter. Transformed bacterial colonies were picked for colony PCR to screen for 
shRNA insertion and further validated by sequencing. 
 
Lentiviral infection of the MBNS lines 
Viral supernatant was produced by transient calcium chloride transfection of human embryonic 
kidney cells (HEK293) cells with 10ug PAX lentiviral packaging vector and 5ug VSV envelope 
vectors and 15ug pSicoR-puro-shRNA vectors. Sixteen hours following transfection, the media 
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was changed to fresh media. Viral supernatant was collected 48 hours after transfection, 
supplemented with Polybrene (8ug/ml) and passed through a 0.45um filter. Dissociated MBNS 
(~10
6
) were resuspended with the filtered viral supernatant and centrifuged for 45 minutes at 
2500 rpm for lentiviral transduction. Puromycin selection (2ug/ml) was applied 1d post-infection 
for 48 hours and on d3 post-infection, the lentivirally-infected MBNS were collected for RNA 
isolation, plated in self-renewal assays, or passaged for maintenance as bulk cultures. 
 
In vitro neurosphere self-renewal assay and limiting dilution assay 
At d3 post-infection, shStat3, shKlf4, and vector control MBNS were dissociated and plated at 
200 cells per well of 6-well plate in neurosphere media. Neurosphere formation was quantified 5 
days post-plating by ImageJ. The neurospheres that emerged from these clonal density assays 
were collected for RNA isolation for gene expression analyses of d8 clonal cultures.  
 For the limiting dilution assays, d3 post-infection shStat3 and shKlf4, vector control 
MBNS were dissociated and plated at 0.3, 1, 3, 10 cells per well of a 96 microwell plate in 
neurosphere media with 48 wells for each cell concentration. Five days post-plating, each well 
was scored for positive or negative neurosphere formation. The self-renewal index, which is the 
number of cells required for the formation of one neurosphere, was determined with the extreme 
limiting dilution assay (ELDA) webtool (http://bioinf.wehi.edu.au/software/elda/). 
 
Analyses of human medulloblastoma gene expression datasets 
Human medulloblastoma gene expression datasets from Northcott et al. (2011) were accessed 
from the Gene Expression Omnibus (GEO) database and the 103 tumor samples were sorted 
based on the annotated subclasses (Shh=33 tumors, Wnt=8 tumors, Class 3=27 tumors, Class 
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4=35 tumors). Expression values were obtained from corresponding gene probes for STAT3 
(3757840), KLF4 (3219215), MYC (311504), BIRC5 (3736290), BCL2L (3902489), MCL1 
(2434438). 
 
In silico promoter analyses 
Promoters of survivin, Mcl1, Bcl-x were retrieved from the Genomatix ElDorado genome 
database. Promoters in Genomatix are defined as regions 500bp upstream and 100bp 
downstream of the transcriptional start site (TSS). Binding site identification was carried out for 
promoters defined by “gold” transcripts, which are those verified by mapping of 5’ full length 
cDNAs or at least 4 CAGE (cap analyses gene expression) by Genomatix MatInspector and 
further analyzed for transcription factor binding sites for STAT3 and GKLF (Klf4). 
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Chapter 3 : Mechanisms of aberrant persistence of cerebellar stem 
cells during medulloblastoma development 
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Introduction 
 
The cell of origin of the SHH subtype of medulloblastomas has been established and 
well-characterized to be a granule cell progenitor (Yang et al., 2008b; Schüller et al., 2008). 
Following the identification of self-renewing, tumor-initiating cells in human primary 
medulloblastomas (Singh et al., 2004), recent studies have examined the potential roles of non-
GCP stem cell populations as the cell of origin in medulloblastoma tumorigenesis. As such, it 
has been shown that a cerebellar stem cell population (Lee et al., 2005), upon transformation 
with an oncogene, can lead to the formation of malignant medulloblastomas (Sutter et al., 2010; 
Pei et al., 2012). Furthermore, Ptch1
LacZ/+
;Trp53
-/-
 medulloblastomas have been characterized to 
contain a population of self-renewing cells expressing NSC markers with the ability for potent 
tumor-initiation upon secondary transplantation (C. Lin thesis).  
The stem cell population of particular interest in the Ptch1
LacZ/+
;Trp53
-/-
 model is the 
aberrantly self-renewing, premalignant cells in the 3 week cerebella. In WT animals, self-
renewal activity is decreased by 3 weeks of age (C. Lin thesis). The persistence of self-renewing 
cells beyond the normal developmental window may be expanding the pool of potential targets 
for malignant transformation, leading to the establishment of a tumor-initiating stem cell 
population. This may be analogous to the abnormal proliferative rests of granule cell progenitors 
in the Ptch1
LacZ/+
 model, which are predisposed for progression to tumor formation upon the 
acquisition of additional oncogenic mutations (Kim et al., 2003). A comprehensive comparison 
of the gene expression profiles between the Ptch1
LacZ/+
;Trp53
-/-
 aberrant tissue stem cells and 
developmental stem cells in both P7 WT and Ptch1
LacZ/+
;Trp53
-/-
 animals will allow for the 
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elucidation of mechanisms and pathways that are allowing the stem cells to persist 
developmentally and contribute to tumorigenesis in the Ptch1
LacZ/+
;Trp53
-/-
 model. 
The strategy described in the previous chapter for studying the self-renewing, tumor-
initiating cell population in Ptch1
LacZ/+
;Trp53
-/-
 tumors relied on the enrichment of these cells by 
in vitro neurosphere culture and the use of heterogeneously expressed markers. 
Ptch1
LacZ/+
;Trp53
-/-
 tumor cells have been reported to undergo changes during adherent, serum-
enriched in vitro tissue culture, such as downregulation of Shh signaling, highlighting concerns 
that in vitro cell lines may not be representative of the original tumor (Sasai et al., 2006). While 
the serum-free neurosphere culture conditions employed may better preserve the in vivo 
characteristics of the Ptch1
LacZ/+
;Trp53
-/-
 medulloblastoma cells, we cannot exclude the 
possibility of the medulloblastoma neurospheres (MBNS) undergoing genetic and/or epigenetic 
changes or clonal selection during the long term passaging of NS cultures. Furthremore, an 
alteration of cell character due to the absence of the normal developmental environment and 
niche signals may inaccurately represent what is occurring in vivo. Therefore, a validated 
prospective marker, allowing for the enrichment directly from the brain would greatly facilitate 
the investigation of these endogenous cell populations. 
CD133 (also known as prominin 1) is widely accepted as a cell surface marker for the 
isolation of NSC and tumor-initiating cells in brain cancers (Lee et al., 2005; Singh et al., 2004), 
as well as a variety of  different solid tumors (Visvader and Lindeman, 2008). While CD133 has 
been extensively used as an established marker for NSC, it has been shown to be 
heterogeneously expressed in NSC and in addition, CD133-negative fractions also contain self-
renewing, multipotent stem cells (Sun et al., 2009). As a CSC marker, the validity of CD133 as a 
definitive marker for fractionating cells with cancer-initiating ability has also been challenged in 
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multiple studies (Beier et al., 2007; Joo et al., 2008; Wang et al., 2006; Chen et al., 2010). This 
must be considered when using CD133 for the isolation of either NSC or CSC and necessitates 
the identification and characterization of other definitive markers. Furthermore, in the MBNS 
lines derived from the Ptch1
LacZ/+
;Trp53
-/-
 tumors, CD133 expression occurs in an exceedingly 
heterogeneous fashion, as clonal lines derived from a highly self-renewing MBNS line showed 
considerable variability in the cell surface expression of CD133, as well as CD15 and CD184, 
other commonly used markers of NSC (C. Lin thesis).  
While markers such as CD133 have been crucial in advancing our understanding of CSC 
in various tumors types, there are limitations of using such cell surface markers. Cell surface 
markers do not necessarily encompass functional significance and, as such, are not reflective of 
the underlying biology of the tissue stem cell that regulates the development of the organ 
(Clevers, 2011). For the same reason, while cancer stem cells hold promise as a potential target 
for therapeutic intervention, the currently employed markers are not functional drug targets that 
will affect CSC survival. 
 Sox2, a SRY family transcription factor, is important for the maintenance of pluripotency 
and self-renewal in various stem cells including ES cells (Avilion et al., 2003, Takahashi and 
Yamanaka, 2006), embryonic and adult NSC (Ellis et al., 2004; Suh et al., 2007), and other 
tissue stem cells of the stomach, testes, lens, and teeth (Arnold et al., 2011; Juuri et al., 2012). In 
the brain, Sox2 expression is restricted to neural progenitors (neuroepithelial cells of the neural 
plate and early neural tube) in the mouse embryo and maintained in the neurogenic regions such 
as the dentate gyrus of the hippocampus and the subventricular zone surrounding the lateral 
ventricles in adults (Ellis et al., 2004). Subsequent fate mapping studies have shown that Sox2-
expressing cells are, in fact, multipotent NSC that can differentiate into multiple lineages in vivo 
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(Suh et al., 2007). Functionally, hypomorphic Sox2 alleles and Sox2 knockout studies in the 
brain have further confirmed the crucial role of Sox2-expressing cells in the neural stem and 
progenitor cell population during neurogenesis (Cavallaro et al., 2008; Ferri et al., 2004; Favaro 
et al., 2009). In the cerebellum, Sox2 expression has been observed in the white matter at P7 
(Sutter et al., 2010), consistent with the presence of prominin
+
 CbSC in the white matter. In 
addition, Sox2 is also observed in the Bergmann glia, both at P7 (Sutter et al., 2010) and in adult 
mice and humans (Sottile et al., 2006; Alcock et al., 2009). It has been suggested that these 
Sox2-expressing Bergmann glia may also represent a novel population of multipotent stem cells, 
but this has not been directly examined.  
The observation of high Sox2 expression in the 3 week Ptch1
LacZ/+
;Trp53
-/-
 cells cultured 
in neurosphere conditions (C. Lin thesis) and the known role of Sox2 in NSC prompted us to 
examine Sox2 as a potential prospective marker in our medulloblastoma model. Preliminary 
results from our lab characterized Sox2 as a marker for the prospective isolation of CbSC in WT 
P7 animals using a Sox2-GFP reporter allele (C. Lin thesis). Isolation of Sox2-expressing cells at 
P7 leads to the fractionation of self-renewal activity and these cells exhibit enriched expression 
of the stem cell gene Hes1 and downregulation of the granule progenitor marker Math1. As 
cerebellar development progresses, the frequency of Sox2-expressing cells diminishes, consistent 
with the reduction of self-renewal activity by 3 weeks of age. Here, I expand and confirm these 
observations and further examine the role of the Sox2-expressing cells in the Ptch1
LacZ/+
;Trp53
-/- 
animals and show that Sox2 also marks the aberrantly self-renewing stem cells in 3 week old 
Ptch1
LacZ/+
;Trp53
-/- 
animals. The establishment of Sox2 as a marker for the prospective isolation 
of CbSC and the aberrant tissue stem cells during medulloblastoma tumorigenesis will be 
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valuable for examining the endogenous mechanisms and pathways that go awry during 
medulloblastoma tumorigenesis. 
 
Results 
 
Sox2-expression marks the self-renewing stem cells in the postnatal day 7 cerebella 
 
To examine if Sox2 can be used as a prospective marker of CbSC, we first analyzed the 
cerebella of WT Sox2-GFP reporter mice. The reporter allele utilized is designed to target the 
endogenous Sox2-locus and replace the Sox2 open reading frame with an EGFP-loxP-neo
R
-loxP 
cassette, while maintaining the upstream regulatory domains (Ellis et al., 2004). This allele has 
been demonstrated to recapitulate the WT Sox2 expression during embryonic and postnatal 
neural development (Ellis et al., 2004). To determine the frequency of Sox2-expressing cells 
during cerebellar development, we dissociated the cerebella from WT animals at P7 and 3 weeks 
and analyzed the Sox2-GFP expressing cells by FACS. At P7, there was a clearly separable 
population of GFP-expressing cells comprising approximately 11% of total cells (Figure 3-1). In 
contrast, there was a greater than 100-fold reduction of GFP-expressing cells by 3 weeks age 
(Figure 3-1), the time-point when cerebellar development has been completed and self-renewal 
activity is undetectable (C. Lin thesis).  
Functionally, to determine if the Sox2-expressing cells can isolate the normal self-
renewing CbSC at P7, we sorted WT Sox2-GFP negative and positive cells into a clonal density 
neurosphere formation assay. Neurosphere formation was only observed in the GFP-positive 
sorted wells, at a frequency of about 4%, and all neurospheres formed expressed GFP (C. Lin 
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thesis, Figure 3-2). These data show that Sox2 can be utilized as a functional marker for the 
prospective isolation of self-renewing stem cells in the P7 cerebella.  
 
 
Figure 3-1 The frequency of Sox2-GFP positive cells is significantly reduced during cerebellar development in 
wild-type animals  
(a) Representative FACS analyses of Sox2-GFP-positive cells in the cerebella of postnatal day 7 and 3 week old, 
control and Sox2-GFP knock-in reporter colony mice. (b) The frequency of Sox2-GFP-positive cells is significantly 
decreased during development from P7 to 3 weeks (data shown as means.d; p=0.0008 by an unpaired t-test). The 
results represent a compilation of experiments performed by C. Lin and R.Yoo.  
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Figure 3-2 Sox2 expression fractionates the self-renewal activity of CbSC in wild-type P7 animals  
(a) Unfractionated, Sox2-GFP-negative, and Sox2-GFP-positive cells were sorted into a low-density neurosphere 
formation assay (2000 cells per well of a 6-well plate). As observed in the fluorescent and bright field images, NS 
were only observed in the Sox2-GFP-positive wells and all NS are GFP-positive. (b) Quantification of self-renewal 
was carried out by counting the number of neurospheres by ImageJ analyses. C. Lin carried out these experiments 
and published figures in Ph.D thesis.  
Enrichment of stem cell gene expression in Sox2-GFP positive CbSC 
 
The isolation of the self-renewing cells by Sox2-expression led us to ask if other 
commonly used NSC markers were co-expressed with Sox2. The Sox2-GFP positive fraction had 
a higher frequency of cells expressing CD133 and CD15 compared to the GFP-negative cells (C. 
Lin thesis, Figure 3-3a). High levels of Stat3 expression in the MBNS and CbSC (Chapter 2), 
suggest that MBNS self-renewal and survival mechanisms utilize conserved pathways present in 
developmental NSC and CbSC. Indeed, expression of Stat3 and target genes Klf4 and c-myc 
were highly upregulated in the Sox2-GFP positive cells (Figure 3-3b). The enrichment of NSC 
markers and genes functionally important in MBNS self-renewal, in particular Klf4, in the Sox2-
positive fraction further supports the validation of Sox2 as a marker for self-renewing CbSC. 
a b 
 94 
 
Figure 3-3 Expression of stem cell genes are enriched in WT P7 Sox2-GFP positive cells  
(a) Cell surface marker CD15 and CD133 expression measured by FACS in Sox2-GFP-negative and positive 
fractions. C. Lin carried out these experiments and published figures in Ph.D thesis. (b) Quantitative RT-PCR 
analyses of Sox2-GFP-negative and positive fractions from wild-type postnatal day 7 cerebella (n=3) show elevated 
levels of genes functionally involved MBNS self-renewal in the GFP positive fractions (Stat3, p=0.0024; Klf4, 
p=0.0342; c-myc, p=0.0578 by unpaired t-test). 
 
Characterization of Sox2-GFP positive cells in Ptch1
LacZ/+
;Trp53
-/-
 chimeras 
 
Following the validation of the preliminary observations in the lab, we next wanted to analyze 
the role of the Sox2-expressing cells in the Ptch1
LacZ/+
;Trp53
-/-
 animals during medulloblastoma 
progression. The Sox2-GFP reporter (Ellis et al., 2004) was knocked into the endogenous Sox2 
locus in Ptch1
LacZ/+
;Trp53
-/-
 ES cells for the generation of chimeric animals. Analyses of 
Ptch1
LacZ/+
;Trp53
-/-
 chimeras have shown that the Ptch1
LacZ/+
;Trp53
-/-
 ES cells preferentially 
colonize the cerebella and these chimeras develop medulloblastomas which recapitulate the 
tumor characteristics and kinetics of colony (germline-mutant) mice (C. Lin thesis). Quantitative 
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analyses by qPCR have indicated that following blastocyst injection, Ptch1 mutant ES cells have 
a competitive growth advantage over the host cells in the developing cerebellum, leading to 
increased ES cell contribution in the cerebellum observed as early P7 in these chimeric mice. 
Therefore, we used this system to generate larger cohorts of Ptch1
LacZ/+
;Trp53
-/-
;Sox2-GFP 
compound mutant animals, genotypes which are obtained at low frequency by breeding, as both 
Ptch1 null (Goodrich et al., 1997) and Sox2 null (Avilion et al., 2003) mutations are embryonic 
lethal. We carried out the analyses in the P7 and 3 week Ptch1
LacZ/+
;Trp53
-/-
;Sox2-GFP 
chimeras, while concurrently breeding the Sox2-GFP allele into the Ptch1
LacZ/+
;Trp53
-/-
 mouse 
colony for analyses of non-mosaic animals.  
In the Ptch1
LacZ/+
;Trp53
-/-
 P7 chimeras, the Sox2-GFP positive cells compose a 
distinguishable population and were consistently present at a higher frequency than WT P7 mice, 
with 26% in the Ptch1
LacZ/+
;Trp53
-/-
 vs. 11% in the WT (Figure 3-4b, Figure 3-1b). In addition, 
the population of Sox2-GFP positive cells remains present in the 3 week old Ptch1
LacZ/+
;Trp53
-/-
 
animals at a frequency of about 5%, 50-fold higher than in the WT 3 week animals (Figure 3-
4b). The GFP-expressing cells in the P7 WT and Ptch1
LacZ/+
;Trp53
-/-
 cerebella are present as a 
distinct cluster of cells based on forward and side scatter analyses by FACS, as shown by 
backgating analyses of the GFP-positive populations (Figure 3-5a). The GFP-positive cells 
observed in the 3 week Ptch1
LacZ/+
;Trp53
-/-
 chimeras also appear to reside in the same distinct 
cluster of cells, a population of cells which is largely diminished by 3 weeks in the WT animals 
Figure 3-5b). These observations suggest that the Sox2-expressing cells in the Ptch1
LacZ/+
;Trp53
-
/-
 animals are a developmentally persistent cell population, existing beyond the normal 
developmental window.  
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Figure 3-4 An identifiable population of Sox2-GFP expressing cells is maintained at 3 weeks in 
Ptch1
LacZ/+
;Trp53
-/-
 animals 
(a) Representative FACS analyses of Sox2-GFP-positive cells in the cerebella of P7 and 3 week old, control and 
Ptch1
LacZ/+
;Trp53
-/-
;Sox2-GFP knock-in reporter chimeric mouse. Sox2-GFP positive cells persist at 3 weeks in the 
Ptch1
LacZ/+
;Trp53
-/-
 animals. (b) The frequency of Sox2-GFP cells is decreased during development from P7 to 3 
weeks in Ptch1
LacZ/+
;Trp53
-/-
 animals (data shown as means.d; p<0.0001 by an unpaired t-test. Open triangles 
represent chimeras and closed triangles denote colony (germline mutant animals).
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Figure 3-5 Backgating analyses of Sox2-GFP positive cells in WT and Ptch1
LacZ/+
;Trp53
-/-
 P7 and 3 week 
animals suggest that the Sox2-positive cell population in the 3 week Ptch1
LacZ/+
;Trp53
-/-
 is a developmentally 
persistent population 
(a) Backgating analyses of the GFP-positive population show that the Sox2-expressing cells comprise a cell 
population that is distinguishable by the FSC and SSC profiles in the WT and Ptch1
LacZ/+
;Trp53
-/- 
P7 cerebella. (b) 
Sox2-expressing cells in 3 week Ptch1
LacZ/+
;Trp53
-/-
 animals are also present as a distinct cell population, as 
recognizable by FSC and SSC profiles. This population is absent in 3 week WT animals.  
 98 
Figure 3-5 (Continued) 
 
 
 
 99 
Sox2-expression isolates the self-renewing cells in 3 week Ptch1
LacZ/+
;Trp53
-/-
 cerebella 
We next asked if the Sox2-expressing cells persisting at 3 weeks in the Ptch1
LacZ/+
;Trp53
-
/-
 animals are functionally associated with the aberrantly self-renewing population by sorting the 
GFP-negative and GFP-positive cells from Ptch1
LacZ/+
;Trp53
-/-
 colony mice directly into the 
clonal-density, neurosphere formation assay. (As further described in the discussion, 
Ptch1
LacZ/+
;Trp53
-/-
 chimeras were not analyzed for self-renewal activity due to confounding 
factors of host cell contribution). As observed in the WT CbSC, neurosphere formation only 
occurred in the GFP-positive fraction and all NS formed were GFP-positive (Figure 3-6). While 
the number of animals analyzed was limited due to low frequency of deriving the 
Ptch1
LacZ/+
;Trp53
-/-
;Sox2-GFP compound mutants by breeding, the results suggest that Sox2-
GFP expression also exclusively marks the aberrantly self-renewing cells in the 
Ptch1
LacZ/+
;Trp53
-/-
 animals at 3 weeks. Furthermore, the GFP-positive population is 
significantly higher in the Ptch1
LacZ/+
;Trp53
-/-
 animals at both P7 and 3 weeks, suggesting that 
deregulation of the stem cell population may be occurring in early postnatal development. 
 
Figure 3-6 Sox2-expressing cells mark the self-renewing cells in the 3 week Ptch1
LacZ/+
;Trp53
-/-
cerebella 
(a) Ptch1
LacZ/+
;Trp53
-/-
; Sox2-GFP positive and negative cells were sorted into the clonal-density NS formation 
assay (2000 cells per well of a 6-well plate). Enrichment of self-renewal activity was observed in the Sox2-GFP 
fraction and all NS are GFP positive. (b) Quantification of self-renewal carried out by ImageJ show an average self-
renewal of 1.8%. Statistical analyses were carried out by one-way ANOVA with a Bonferroni post test. 
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Figure 3-7 Summary of the frequency of GFP-expressing cells in P7 and 3 week WT Sox2-GFP and 
Ptch1
LacZ/+
;Trp53
-/-
 Sox2-GFP animals 
Comparison of the frequency of GFP-positive cells between the WT and Ptch1
LacZ/+
;Trp53
-/-
 Sox2-GFP animals at 
P7 and 3 weeks shows a significant increase in GFP-positive cells in the Ptch1
LacZ/+
;Trp53
-/-
 genotype at both 
timepoints. Statistical significance was determined by individual t-tests between the two different genotypes.  
 
Differential gene expression between P7 WT and 3 week Ptch1
LacZ/+
;Trp53
-/-
 Sox2-GFP 
positive cells 
 
 To determine if there are differences in gene expression between the Sox2-expressing and 
non-expressing cells, we sorted the GFP-negative and positive fractions from P7 WT colony 
mice and 3 week Ptch1
LacZ/+
;Trp53
-/-
 chimeras and colony mice for the isolation of RNA. Re-
sorting the GFP-negative and positive fractions further improved the purity of the FACS 
fractionation, ensuring expression analyses from cells highly enriched for Sox2-expressing and 
non-expressing cells (Figure 3-8). 
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Figure 3-8 Sox2-GFP negative and positive cells were re-sorted to increase purity for RNA isolation for gene 
expression analysis  
Representative examples of FACS plots of GFP expression in P7 WT and 3 Week Ptch1
LacZ/+
;Trp53
-/-
;Sox2-GFP 
cerebella as analyzed by MoFlo. GFP-negative and positive fractions were collected and each fraction was re-sorted 
to obtain an increased purity in the fractions.  
For validation of the FACS sorts, we examined the expression of the GFP transgene and 
observed a 50-fold enrichment in the WT P7 Sox2-GFP fractions and about 20-fold enrichment 
in all of the 3 week Ptch1
LacZ/+
;Trp53
-/-
 Sox2-GFP positive fractions, relative to a P7 WT Sox2-
negative control. We next examined the gene expression of a small panel of stem cell, granule 
cell progenitor, and Shh pathway activation genes in the Sox2-positive fractions, which were all 
normalized to a P7 WT Sox2-negative sample. In the WT P7 cerebella, enrichment of Sox2 
expression and upregulation of Hes1, a gene important in the self-renewal of NSC (Nakamura et 
al., 2000) was negatively correlated with the expression of Math1, a marker for cerebellar 
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granule neurons (Figure 3-9a). In contrast, in the 3 week Ptch1
LacZ/+
;Trp53
-/-
 animals, Sox2 
expression was not associated with a depletion of Math1 expression, but showed an increase in 
Math1 in comparison to the WT P7 Sox2-negative fraction (Figure 3-9b). In addition, Gli1 and 
Gli2 expression was also slightly higher in the 3 week Ptch1
LacZ/+
;Trp53
-/-
;Sox2-positive cells. 
This suggests that while the 3 week Ptch1
LacZ/+
;Trp53
-/-
;Sox2-positive cells represent a 
population of aberrantly self-renewing stem cells, they are also responsive to the differentiation 
signals of the Shh pathways, which are active during cerebellar development, and may be 
maintaining characteristics of both cerebellar stem cell and granule cell progenitors.  
 
 
Figure 3-9 Differential gene expression of granule cell progenitor markers in the 3 week Ptch1
LacZ/+
;Trp53
-/-
; 
Sox2-GFP positive cerebellar cells  
qRT-PCR expression analyses of stem cell markers Sox2 and Hes1 and granule cell progenitor markers Math1, Gli1 
and Gli2 in Sox2-positive sorted cells from (a) wild-type P7 colony mice (n=8) and (b) Ptch1
LacZ/+
;Trp53
-/-
 3 week 
chimeras (n=4). Fold change in expression is represented relative to P7 WT Sox2-negative cell fractions, which is 
normalized to 1. 
a b 
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Discussion 
 
The Ptch1
LacZ/+
;Trp53
-/- 
mouse model of medulloblastoma reveals a population of self-
renewing cells from the tumor and at 3 weeks, a developmental time-point when normal 
cerebellar development is complete and self-renewal activity is largely non-existent (C. Lin 
thesis). While the MBNS have potent tumor-initiating capability, the aberrantly self-renewing 
cells from 3-week-old mice have not yet undergone loss of heterozygosity of the Ptch1 allele, the 
tumor-initiating event in the Ptch1 model, and do not form tumors (Yang et al., 2008b) (C. Lin 
thesis). While in vitro enrichment of this pre-malignant tissue stem cell population by serial 
neurosphere culture has been valuable in uncovering the mechanisms for tumor-initiating events, 
a prospective marker allowing for isolation of an endogenously occurring, bona fide self-
renewing tissue stem cell circumvents concerns about tissue culture-induced changes or 
enrichment of heterogeneous cell types. Here we show that Sox2-GFP expression fractionates 
the self-renewal activity in both the P7 WT and 3 week Ptch1
LacZ/+
;Trp53
-/- 
cerebella, thus 
validating Sox2 as a marker for the prospective isolation of the endogenous self-renewing CbSC 
as well as the aberrant CbSC. This novel marker will have great utility for further examination of 
stem cell regulation during medulloblastoma tumorigenesis.  
 
Sox2 as a prospective marker for self-renewing normal and aberrantly persistent CbSC 
 Critical for the validation of CSC markers is the strict correlation between marker 
expression with bona fide self-renewal activity (Clarke et al., 2006). For example, it has been 
shown that CD133, a widely used cell surface marker, does not strictly isolate stem cell activity, 
as CD133-negative cells also demonstrated properties of self-renewal (Sun et al., 2009). 
Variations in FACS isolation with cell surface marker staining have also been reported to be 
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subject to inconsistencies due to antibody differences and other technical variations (Visvader 
and Lindeman, 2012). By using an endogenous reporter for Sox2-expression, we show that the 
prospective isolation of Sox2-expressing cells fractionated the self-renewing, developmental 
CbSC at P7. No NS formation was observed in the GFP-negative fraction and all the 
neurospheres that formed were GFP-positive. By 3 weeks of age, the frequency of Sox2-
expressing cells is significantly reduced, consistent with the abolished self-renewal activity at 3 
weeks in WT animals. In contrast, although at a significantly lower frequency than the P7 
Ptch1
LacZ/+
;Trp53
-/-
 animals, GFP-positive cells were reliably sorted from every 3 week 
Ptch1
LacZ/+
;Trp53
-/-
 animal. However, the functional significance of the wide variability in the 
frequency of Sox2-positive cells in the 3 week Ptch1
LacZ/+
;Trp53
-/-
 cerebella is unknown. 
Nonetheless, Sox2-expression also unambiguously marked the self-renewing cells in the 
developmentally persistent stem cells in the 3 week Ptch1
LacZ/+
;Trp53
-/- 
cerebella. While the 
mechanism of developmental persistence is unknown, the absence of GFP-negative NS suggests 
that the expression of Sox2 may be functionally important in the self-renewal of CbSC, further 
supporting Sox2 as a robust marker. The functional role of Sox2 in NSC maintenance and 
neurogenesis is well-established and it’s role in CSC self-renewal, specifically, has also been 
demonstrated in glioblastoma (Gangemi et al., 2009) and breast cancer (Leis et al., 2011). 
Alternative to the hypothesis of the persistence of Sox2-positve CbSC during development, we 
must also consider the possibility of a Sox2-expressing population arising de novo during the 
development of Ptch1
LacZ/+
;Trp53
-/-
 animals, rather than an endogenous Sox2-expressing 
population persisting from early development. To address this, an inducible Sox2-GFP allele 
may be utilized to track the Sox2-expression during development. Using the Sox2-
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CreER;ROSA26-Isl-EYFP mice, tamoxifen-induced recombination can be carried out to activate 
the expression of the fluorescent marker then tracked during cerebellar development. 
  
Analyses of Ptch1
LacZ/+
;Trp53
-/-
;Sox2-GFP chimeras 
It must be noted that the analyses of the Ptch1
LacZ/+
;Trp53
-/-
;Sox2-GFP chimeras have 
caveats. While the complete colonization of the cerebella by the Ptch1
LacZ/+
;Trp53
-/-
 ES cells in 
chimeric mice has been carefully validated (C. Lin thesis), the effect of the Sox2-GFP reporter 
allele on this colonization phenotype has not been directly examined. The Sox2-GFP reporter 
allele is knocked into the endogenous Sox2 promoter and targeting results in the inactivation of 
one Sox2 allele. While the Sox2 heterozygous animals are viable and display no overt 
abnormalities (Avilion et al., 2003), given the importance of Sox2 in NSC, the possibility of a 
haploinsufficient effect of Sox2 heterozygosity on the colonization phenotype cannot be 
disregarded. The analyses of P7 Ptch1
LacZ/+
;Trp53
-/-
;Sox2-GFP chimeras demonstrate that this in 
fact, may be the case; the formation of GFP-negative neurospheres was observed in the Sox2-
GFP negative fractions in the low-density neurosphere formation assay, implying that there may 
be WT host-derived contamination. To circumvent the confounding factors introduced by the 
contamination of the host cells WT for Sox2, further analyses of Ptch1
LacZ/+
;Trp53
-/-
;Sox2-GFP 
animals were only carried out with colony (germline-mutant) animals. 
  
Differential gene expression between the Sox2-GFP expressing P7 cerebellar stem cells and 3 
week aberrant tissue stem cells 
Despite the complications that may arise from the chimeric analyses, as the host cells 
lack the GFP allele, the Sox2-GFP-positive fractions from the chimeras are all necessarily 
 106 
derived from ES cells, and thus have been used for analyses of gene expression. In the case of 
the GFP-negative cells, although wild-type host cells are not expected to express Sox2 at 3 
weeks, they do retain both copies of the WT Sox2 allele and may confound the analyses of gene 
expression in the 3 week Ptch1
LacZ/+
;Trp53
-/-
 Sox2-negative fractions. Therefore, chimera-
derived GFP-negative cells from 3 week old mice have not been included in the gene expression 
analyses; the Sox2-GFP negative fractions of the WT Sox2-GFP animals derived from the 
colony were used as controls.  
In the WT P7 Sox2-GFP positive cells, there was an enrichment for the expression of 
Hes1, a stem cell marker, and Sox2-expression was negatively correlated with Math1. This 
pattern of gene expression is consistent with the Sox2-positive cells representing CbSC and the 
Sox2-negative cells containing the Math1 lineage-restricted granule cell progenitors, which are 
actively proliferating at P7. The maintenance of the Math1 expression and to a lesser extent Gli1 
and Gli2 expression in the 3 week Ptch1
LacZ/+
;Trp53
-/-
 Sox2-positive cells suggests that the 
aberrantly self-renewing cells are responsive to the Shh signaling pathway for granule-lineage 
determination, but also concurrently exhibit NSC characteristics. Whether this is due to a 
resistance to differentiation or an ectopic acquisition of stem cell behavior in differentiated 
granule cell progenitors are both potential mechanisms that may be explored. bFGF, which is 
present in NS culture conditions, has been shown to abolish Shh-induced proliferation and 
promote differentiation of the GCP (Fogarty et al., 2007). Neurosphere formation of the 
Ptch1
LacZ/+
;Trp53
-/-
 Sox2-positive cells from 3 week old animals suggests that these cells are 
exhibiting a block in differentiation.  
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Future Studies 
Using the Sox2-GFP positive and negative sorted fractions, a genome-wide expression 
analyses will be carried out. There will be great utility for the genome-wide expression profiles 
and signatures of the specific subsets of cell populations, such as CSC and premalignant stem 
cells in the Ptch1
LacZ/+
;Trp53
-/- 
model. Potentially, gene expression profiles specifically 
identifying the CSC population may have important clinical implications. In fact, in the 
hematopoietic system, the characterization and comparison of HSC and leukemia stem cell 
expression profiles have allowed for the accurate prediction of patient outcomes (Eppert et al., 
2011). It can be imagined that the identification of a medulloblastoma stem cell-specific 
expression profile can be used to better predict prognoses and improve risk stratification. Insights 
into the mechanisms and pathways involved in the persistence of aberrant tissue stem cells will 
also be important. For example, if the aberrantly persisting stem cells are expanding the pool of 
targets for oncogenic transformation, reduction or elimination of this population may decrease 
the frequency of cells acquiring the transforming mutation (Wicha et al., 2006), allowing for 
earlier therapeutic intervention. 
Sox2-positive cells can also be isolated from postnatal day 7 Ptch1
LacZ/+
;Trp53
-/- 
Sox2-
positive animals. By comparing this to the WT Sox2-GFP cells, this will allow us to determine if 
the Ptch1
LacZ/+
;Trp53
-/- 
genotype exhibit aberrant patterns of gene expression early on in 
cerebellar development.  
Methods 
 
ES cell generation 
V6.5 wild-type ES cells were electroporated with the Sox2-GFP targeting vector (Ellis et al., 
2004, generous gift from K. Hochedlinger) and selected in neomycin for 7 days. The Sox2-GFP 
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targeting vector was modified to exchange the neomycin-selection cassette with a puromycin-
selection cassette for electroporation into Ptch1
LacZ/+
;Trp53
-/-
 ES cells. Neomycin- and 
puromycin-resistant colonies were picked and expanded for genotyping for targeting by a 
quantitative qPCR for genomic copy number of the Sox2 allele. 
 
Generation of mouse chimeras and animal husbandry 
Blastocyst stage embryos were isolated from CD-1 superovulated females crossed to CD-1 males 
(Charles River) at 2.5dpc and cultured in KSOM-AA overnight. Expanded blastocysts were 
injected with 5-10 WT Sox2-GFP and Ptch1
LacZ/+
;Trp53
-/-
 Sox2-GFP ES cells and transferred to 
2.5dpc pseudopregnant CD-1 females. WT Sox2-GFP chimeric males were crossed to Albino/B6 
females and germline transmission was confirmed by genotyping F1 pups for the Sox2-GFP 
allele. Sox2-GFP mice were bred into the Ptch1 and Trp53 mutant background for generation of 
Ptch1
LacZ/+
;Trp53
-/-
 animals. Ptch1
LacZ/+
;Trp53
-/-
 Sox2-GFP chimeras were used directly for 
experiments. Mice were maintained in pathogen-free conditions at Boston Children’s Hospital 
and procedures were performed following approval by the Institutional Animal Care and Use 
Committee (IACUC). 
 
Flow cytometry  
Cerebellar tissues were dissociated into single cell suspension by mincing with a razor blade and 
followed by trituration in NS media, washed and resuspended in PBS+2mM EDTA+0.5% BSA 
and run on a BD FACS Aria and Beckman Coulter/Dako MoFlo at the HSCI/Joslin Flow 
Cytometry Core. Samples were stained with 7-AAD (BD Biosciences) for exclusion of dead 
cells and gated on the GFP-positive or GFP-negative fractions. For the low-density neurosphere 
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formation assay, cells were sorted directly into a 6-well plate with neurosphere culture media 
(DMEM:F12 containing B27 Supplement (Invitrogen), 20ng/ml bFGF (Invitrogen), 20ng/ml 
EGF (Invitrogen), and 100U/ml penicillin/streptomycin (Invitrogen)). 
 
Expression analyses by quantitative PCR 
Sox2-GFP-positive and negative sorted cells were pelleted and resuspended in Trizol Reagent 
(Invitrogen) for RNA isolation, using RNase-free glycogen (Invitrogen) as a carrier. Isolated 
RNA was treated with DNaseI (New England Biolabs) and synthesized as cDNA using the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative RT-PCR was 
carried with the SYBR Green PCR Master Mix (Applied Biosystems) using cDNA dilutions 
determined by prior primer optimization experiments. GFP, Sox2, Gli1, Gli2, Hes1, and Math1 
expression was normalized to Gapdh and changes in gene expression were determined by the 
ddCT method and represented as expression levels relative to the P7 WT Sox2-GFP negative 
control. 
 
Primers:   
Gapdh:  5' GTTGTCTCCTGCGACTTCA 3’; 5’ TGGTCCAGGGTTTCTTACTC 3’  
GFP: 5’ GAACGGCATCAAGGTGAAC 3’ ; 5’ CTTGTACAGCTCGTCCATG 3’ 
Sox2: 5’ CCGAGGAGGAGAGCGCCTGT -3’; 5’- GCTCGAGACGGGCGAAGTGC 3’  
Gli1: 5’ TTCAAGGCCCAATACATGCT 3’; 5’ GCGTCTTGAGGTTTTCAAGG 3’  
Gli2: 5’ GGTCTCTTGGAGGACAGCAG 3’; 5’ TCTCATGTCAATCGGCAAAG 3’  
Hes1: 5’ ATGCCGGGAGCTATCTTTCT 3’; 5’ ACACCGGACAAACCAAAGAC 3’  
Math1: 5’ ACAGGTCCTTCTGTGCCATC 3’; 5’ GCTTCCTCTGGGGGTTACTC 3’  
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Prior to the emergence of  “medulloblastomics”, medulloblastoma has been largely 
considered and studied as a single-entity disease but it has become evident that it is, in fact, a 
heterogeneous collection of tumors comprised of distinct molecular subtypes (Northcott et al., 
2012). The generation and examination of subtype-matched mouse models have shed light on 
discrete mechanisms for disease progression and the cell of origin (Kool et al., 2012). Now with 
the core four groups of medulloblastoma established, studying the heterogeneity within a 
subgroup for further subcategorization may also be relevant for the investigation of targeted 
therapies. As such, it has been shown that within the SHH tumors, pediatric and adult tumors are 
transcriptionally, genetically, and clinically discrete (Northcott et al., 2011a). Work in our lab 
has also shown that the Ptch1
LacZ/+
 and Ptch1
LacZ/+
;Trp53
-/-
 genotypes also result in functionally 
distinct tumors in mice. Notably, the Ptch1
LacZ/+
;Trp53
-/-
 model results in aggressive tumors with 
a population of self-renewing and tumor-propagating cells (C. Lin thesis). In addition, while the 
cell of origin in the SHH tumors has been established as the granule cell progenitors (GCP), 
cerebellar stem cells (CbSC) have been suggested as another potential tumor-initiating cell 
population (C. Lin thesis). Recent work has also shown that postnatal CbSC transformed with the 
overexpression of c-myc can lead to tumor-initiation upon transplantation (Kawauchi et al., 
2012; Pei et al., 2012). The presence of a self-renewing, tumor-initiating stem cell population in 
the Ptch1
LacZ/+
;Trp53
-/-
 tumors and the observation of an aberrantly self-renewing, premalignant 
population of CbSC further substantiated the examination of stem cell regulation in this 
medulloblastoma model.  
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In Chapter 2, we wanted to examine the pathway dependencies and plasticity 
mechanisms of the self-renewing, tumor-initiating cells in the Ptch1
LacZ/+
;Trp53
-/-
 
medulloblastomas. Specifically, we asked if an endogenously active pluripotency transcription 
factor network could be utilized for the survival and maintenance of self-renewal of the 
Ptch1
LacZ/+
;Trp53
-/-
 MBNS. The observation of phenotypic plasticity and conversion of the 
tumor-initiating medulloblastoma neurosphere cells in the ES culture conditions in the absence 
of ectopic factors led us to ask if epigenetic regulation such as DNA methylation alterations 
could be involved. This subsequently led to the identification of reprogramming factor Klf4 as a 
gene important in the mediating both the MBNS plasticity and self-renewal. 
The functional role of pluripotency genes in mediating cancer stem-like phenotypes has 
been described. For example, Oct4 expression induces the dedifferentiation of melanoma cells 
and leads to the acquisition of CSC characteristics, such as expression of melanoma stem cell 
markers and multipotent differentiation (Kumar et al., 2012). Furthermore, the induction of 
pluripotency gene expression in immortalized breast epithelial cells results in the formation of 
cancer stem-like cells with tumor-initiating ability and interestingly, an increased resistance to 
chemotherapeutic agents (Nishi et al., 2013). The similarities between the expression profiles of 
ES cells and high-grade, malignant tumors (Ben-Porath et al., 2008) further provide a rationale 
for the “oncogenic reprogramming” model for the generation and maintenance of CSC. 
However, the examination of the role of c-myc in the transcriptional profiles of cancer cells has 
revealed that the ES gene signature is merely reflective of an activated c-myc signature of tumors 
(Kim et al., 2010). Functionally, the role of c-myc has been further shown to globally amplify the 
output of existing transcriptional programs by increased binding at the promoters and enhancers 
of genes already activated (Lin et al., 2012), shedding light on the mechanism for the diverse 
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effects of c-myc observed in various tumors. If c-myc is functioning in a similar manner in the 
Ptch1
LacZ/+
;Trp53
-/-
 medulloblastomas, it can be postulated to be playing a role in promoting 
stem cell-driven tumorigenesis by amplifying the activated stem cell signatures in the aberrant 
tissue stem cells. Though the potential mechanism of dedifferentiation of GCP or CbSC during 
Ptch1
LacZ/+
;Trp53
-/-
 tumor progression has not been directly addressed in this study, the plasticity 
of tumor cells to alter cellular states and respond to different environmental variations remains an 
plausible mechanism for tumor stem cell survival, metastases and treatment evasion. 
Klf4 overexpression has been shown to abrogate the necessity for exogenous LIF in ES 
culture media for the maintenance of ES cells in an undifferentiated state (Zhang et al., 2010). 
Klf4 is also a known direct downstream target of the Stat3 pathway, crucial in ES cells (Niwa et 
al., 1998), NSC (Yoshimatsu et al., 2006; Androutsellis-Theotokis et al., 2006) and observed to 
be aberrantly activated in various tumors (Yu and Jove, 2004), including brain tumors (Schaefer 
et al., 2002; Yang et al., 2008a). Based on the observation of LIF independence and Stat3 
overexpression and constitutive activation in the MBNS, we hypothesized that upstream Stat3 
signaling may be mediating the function of Klf4. However, Stat3 kd by pharmacological 
inhibition and RNAi both led to a partial and non-significant effect on the self-renewal of the 
MBNS, especially in the limiting dilution assay. Furthermore, Klf4 expression levels rebounded 
in Stat3 kd neurospheres, suggesting that the regulation of Klf4 can occur in a manner 
independent of the canonical LIF/Stat3 pathway to maintain clonogenic growth. The Stat3-
independent compensatory mechanism remains to be determined, but highlights the importance 
of uncovering the multiple modes of Klf4 regulation for a more extensive understanding of the 
transcriptional networks regulating the self-renewal and survival pathways in the tumor-initiating 
cells. 
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Through the modulation of Stat3 and Klf4 levels, we observed that the expression of Klf4 
is crucial for MBNS plasticity and self-renewal and can be regulated in a Stat3-independent 
manner. The novel role of Klf4 in maintaining the clonogenic growth of self-renewing cells in a 
medulloblastoma model provides the rationale to further examine the function of KLF4 in human 
medulloblastomas, specifically in the class of human tumors with the poorest rates of survival. 
While KLF4 expression is not enriched in the Class C human medulloblastomas (data not 
shown), which have the lowest survival rates, if it is functioning in a small subset of self-
renewing cells within the bulk tumor, the expression levels may not be reflected in the gene 
expression analysis of bulk tumors. The expression levels of KLF4 specifically in a population of 
cells enriched for self-renewal, such as prominin 1 positive cells, may be important and 
interesting to analyze. Further, the therapeutic potential of KLF4 inhibition can also be 
considered. A pilot experiment in the MBNS testing the synergy between Klf4 kd and gamma 
irradiation, a treatment modality used in human medulloblastoma patients, suggests that the kd of 
Klf4 may sensitize the cells to doses of radiation ineffective in cells with WT levels of Klf4, as 
measured by a decrease in NS formation frequency with the combination of Klf4 kd and 
irradiation. Further validation of this experiment must be carried out, but these initial 
observations provide an additional motivation for studying the role of Klf4 in the survival of the 
tumor-initiating, self-renewal population in medulloblastomas. In the MBNS, the maintenance of 
antiapoptotic gene expression was associated with the compensatory upregulation of Klf4. While 
this is suggestive of an antiapoptotic role of Klf4, which has been reported (Ghaleb et al., 2007), 
functional apoptosis following Klf4 kd must first be addressed and can be measured by a variety 
of assays such as TUNEL staining, cleaved Caspase-3 staining in the MBNS. During Ras-
mediated transformation, Klf4 has been shown to directly repress the transcription of p53, 
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leading to resistance to DNA-damage mediated apoptosis (Rowland et al., 2005). Since a 
mechanism for radiation sensitization by Klf4 inhibition will be a Trp53-independent mechanism 
if demonstrated in Ptch1
LacZ/+
;Trp53
-/-
, this will be important, considering that human 
medulloblastoma patients harboring somatic TP53 mutations exhibit early disease recurrence and 
lack of long-term survival compared to patients with WT TP53 receiving the same craniospinal 
irradiation and chemotherapy (Tabori et al., 2010).  
The compensatory mechanism of transcription factors in related pathways may be a 
general mechanism of CSC to exhibit plasticity and survival against the environmental 
challenges they must overcome, such as irradiation or adaptation to a new niches during 
metastases. Therefore, it will be important to characterize such mechanisms and determine if 
multiple pathways must be targeted for effective treatment. In contrast to oncogene addiction, in 
which tumor cells are dependent on a specific gene for survival, CSC may exhibit flexibility in 
the regulation of the expression of functionally redundant genes important for its survival and 
therefore require targeting multiple genes to exert a “synthetic lethality” effect (Luo et al., 2009).  
Further expanding on the idea of targeting multiple pathways in CSC, our observations 
may provide the rationale for the combinatory inhibition of the Shh pathway and pathways 
important for self-renewal. Since the effect of Stat3 inhibition alone on self-renewal was partial, 
the inhibition of the Shh pathway in combination with Stat3 inhibition is a potential approach 
that may be examined. Considerable efforts have been made to target the Stat3 and Shh pathways 
in medulloblastomas and other tumors, therefore small molecule inhibitors are readily available. 
Constitutive Stat3 activation is observed in human medulloblastomas (Schaefer et al., 2002; 
Yang et al., 2008a), with the NSC survival-associated phosphorylation of Ser727 (Androutsellis-
Theotokis et al., 2006) occurring as a tumor-specific activation (Schaefer et al., 2002; Yang et 
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al., 2008a). Multikinase inhibitors whose activities are associated with the inhibition of Stat3 
phosphorylation (Yang et al., 2008a; 2010a), selective inhibitors of the Jak2/Stat3 pathway (ie. 
JSI-124) (Lo et al., 2008), and Stat3 DNA binding site inhibitors (Ball et al., 2011) have all been 
shown to reduce proliferation and induce apoptosis in multiple medulloblastoma cell lines. 
Interestingly, JSI-124 treatment was shown to sensitize the medulloblastoma cells to an 
otherwise ineffective chemotherapeutic, BCNU, and displayed synergy with cisplatin in 
inhibiting medulloblastoma cell survival (Lo et al., 2008). Importantly, both chemotherapeutics 
are currently used to treat medulloblastoma patients in the clinic. Specifically in brain tumor 
stem cell populations, small molecule Stat3 inhibitors (Stattic and STA-21) have been 
demonstrated to inhibit glioblastoma stem cell neurosphere formation and induce apoptosis 
(Sherry et al., 2009; Villalva et al., 2011). However, the effect of Stat3 inhibition on the 
expression of target gene Klf4 has not been examined in these studies and remains to be 
determined if the therapeutic function of Stat3 inhibitors is mediated by a downstream inhibition 
of Klf4, as suggested in our work.  
 Given the well-established role of the SHH pathway in cerebellar and medulloblastoma 
development, a number of SHH inhibitors, including Cyclopamine and SMO antagonist, 
HhAntag have been reported to be effective in slowing the growth of SHH tumors (Berman et 
al., 2002; Romer et al., 2004). In particular, SMO antagonist GDC-0449 has had partial success 
in the clinic, whereby rapid tumor regression was observed following GDC-0449 treatment in an 
adult patient with a SHH pathway-activated tumor (Rudin et al., 2009). However, tumor relapse 
occurred rapidly and widespread dissemination followed. The mechanism of resistance was 
subsequently identified to be a somatic mutation in the drug binding site in SMO, which did not 
exist prior to treatment (Yauch et al., 2009). To overcome resistance mechanisms, new inhibitors 
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effective against the GDC-0449-resistant mutants were identified in a small molecule inhibitor 
screen, but additional resistance mechanisms occurring downstream of SMO prompted the 
targeting of an alternative pathway for overcoming resistance (Dijkgraaf et al., 2011). 
Importantly, GDC-0449-resistant mutants were sensitive to PI3K/Akt inhibition, suggesting this 
pathway as a potential target in GDC-044- resistant tumors (Dijkgraaf et al., 2011). These 
observations are consistent with the idea that a unique population of cells within the tumor may 
possess the ability to utilize multiple compensatory pathways for survival. Therefore, studying 
the self-renewing cells that specifically exhibit properties of plasticity and survival in varying 
growth conditions may also present a novel strategy for examining resistance mechanisms. 
 
In Chapter 3, we sought to validate Sox2 as a prospective marker for the isolation of 
postnatal CbSC and further establish it as a marker for the enrichment of the aberrantly self-
renewing, premalignant stem cells in the Ptch1
LacZ/+
;Trp53
-/-
 animals. Culturing glioblastoma 
cells as neurospheres in serum-free culture in the presence of bFGF and EGF has been described 
for the isolation of self-renewing, multipotent, tumor-initiating cells expressing NSC markers 
(Yuan et al., 2004) and maintenance of the characteristics of the primary tumors (Lee et al., 
2006). Only the neurosphere cells, but not the non-sphere-forming cells, were able to initiate 
tumor-formation in vivo (Yuan et al., 2004). Similarly, in the absence of appropriate markers for 
CSC for the Ptch1
LacZ/+
;Trp53 medulloblastomas, we first utilized the neurosphere culture-based 
system to isolate and characterize pathways important in self-renewal and survival. The 
Ptch1
LacZ/+
;Trp53 MBNS exhibit self-renewal, as demonstrated by limiting dilution assays and 
the derivation of clonal lines, high expression of NSC markers CD133, nestin, and possess potent 
ability for tumor-initiation in vivo (C. Lin thesis). We must note, however, that the multipotent 
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differentiation capability of these medulloblastoma-initiating neurosphere cells has not been 
directly addressed. Growth factor withdrawal from the Ptch1
LacZ/+
;Trp53 MBNS suggests a 
block in differentiation as observed by the maintenance of Sox2 expression following bFGF and 
EGF removal. The withdrawal of growth factors from the aberrant Ptch1
LacZ/+
;Trp53 tissue stem 
cells, also enriched by neurospheres cultures, however, exhibited a reduction in Sox2 expression. 
The neurosphere culture method has also been utilized to isolate bFGF and EGF-responsive 
multipotent CbSC from the postnatal d7 cerebella (Lee et al., 2005). The persistence of a bFGF 
and EGF-responsive population in 3 week old Ptch1
LacZ/+
;Trp53 animals at a time point when 
cerebellar development is complete, suggests an developmentally persistent population of stem 
cells. Cerebellar granule progenitor cells proliferate in response to SHH during cerebellar 
development, but bFGF directly inhibits SHH signaling (Fogarty et al., 2007). The CbSC may 
have a block in differentiation that allows them to persist as stem cells, however, the possibility 
of progenitor cells dedifferentiating to stem-like cells with neurosphere-forming capability also 
cannot be ruled out. To further this question, a marker for the prospective genetic marking of 
stem cells is necessary, which we have started to address by examining the potential for Sox2 as 
a prospective marker for the aberrant CbSC during medulloblastoma progression.  
Using an endogenous Sox2-GFP reporter allele, we observed that the prospective 
isolation of Sox2-expressing cells was able to fractionate the self-renewing activity in the WT 
CbSC and the aberrant tissue stem cells. Preliminary expression analyses with a small subset of 
genes also show that expression of Math1, a marker for GCP, is inversely correlated with Sox2 
expression in the WT CbSC. However, in the 3 week Ptch1
LacZ/+
;Trp53
-/-
;Sox2-GFP cells, the 
expression of Math1, Gli1 and Gli2 suggest that the responsiveness to the Shh signaling for 
granule cell differentiation is intact, but stem cell characteristics are also maintained. Genome-
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wide transcriptional profiling of these aberrantly self-renewing stem cells will provide further 
insight into the mechanisms and pathways of developmental persistence and block in 
differentiation. In addition, comparison of the 3 week aberrant tissue stem cells and the P7 CbSC 
will allow us to identify pathways or therapeutic targets specific to the aberrant population, 
which is especially critical given that medulloblastomas are developmental tumors and 
nonspecific effects of therapeutics may have dire side effects in young patients. Comparison of 
the WT and Ptch1
LacZ/+
;Trp53
-/-
;Sox2-GFP CbSC at P7 may also provide insight into the early 
mechanisms of stem cell deregulation. 
For future studies, the Sox2-GFP reporter can also be utilized to determine the 
localization of Sox2-expressing cells during cerebellar development and malignant progression. 
At P7, Sox2 expression is observed in the white matter, coinciding with the location of the 
CD133-positive CbSC (Lee et al., 2005). With further maturation of the cerebellum, by P25 and 
in the adult, Sox2 expression is restricted to the Purkinje cell layer, specifically marking the 
Bergmann glia (Sottile et al., 2006). The location of the Sox2-expressing population in the 3 
week Ptch1
LacZ/+
;Trp53
-/-
 cerebella is currently unknown. Based on the current knowledge of 
Sox2-expression during normal cerebellar development, it can be postulated that the Sox2-
positive cells are marking the subset of CbSC present in the white matter, aberrantly persisting 
due to a deficiency in differentiation. Alternatively, Sox2-expression may be marking an 
expanded Sox2-positive Bergman glial cell population, which has been proposed as a potential 
NSC population that has yet to be characterized (Sottile et al., 2006). Another possibility is the 
dedifferentiation of lineage-restricted GCP cells of the EGL, due to an acquisition of stem cell 
character during progenitor expansion. Histological or immunohistochemical analyses of Sox2 
expression in both WT and Ptch1
LacZ/+
;Trp53
-/-
 tissues will allow for us to determine the location 
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of the Sox2-expressing cells and further our understanding of the possible cell of origin and 
mechanisms of Ptch1
LacZ/+
;Trp53
-/-
 medulloblastoma progression. In addition, similar to the 
recent lineage tracing studies which identified bona fide CSC in vivo, with an inducible Sox2-
GFP reporter, lineage tracing can be carried out to examine the individual contribution of the 
Sox2-expressing cells during medulloblastoma progression and if the progeny of the Sox2-GFP 
cells do, in fact, mark the resultant tumor in the Ptch1
LacZ/+
;Trp53
-/-
 animals. 
The Sox2-GFP marker may be useful, not only in the developmental context but also as a 
marker for the MBNS in the endpoint Ptch1
LacZ/+
;Trp53
-/-
 tumors. The analyses of Sox2-
expressing cells in the tumors may yield greater insight into the potential role for 
dedifferentiation or reprogramming-like mechanisms in CSC. The use of long-term passage 
MBNS lines for the in vitro reprogramming assay has made it difficult to address whether or not 
the cells with the capability for growing in ES culture conditions were a preexisting population 
in the tumor or a result of long-term culture-induced changes. The direct isolation of the Sox2-
GFP population into ES culture conditions in the in vitro reprogramming assay will allow us to 
determine more definitively if a pre-existing, endogenous population of stem cells with the 
ability for reprogramming is preexisting in the tumor. 
 
In a tentative hypothesis for the aberrant persistence of tissue stem cells in the 
Ptch1
LacZ/+
;Trp53
-/- 
animals (Figure 4-1), we postulate that a deregulation of stem cell self-
renewal and resistance to differentiation may be mediated by collaboration between the loss of 
Trp53 function and activated Shh signaling. This is suggested by the increase in basal level of 
self-renewal in 3 week Trp53
-/-
 animals (C. Lin thesis), which is consistent with the role of p53 
in the maintenance of NSC populations (Meletis et al., 2006) and dedifferentiation during 
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somatic reprogramming (Krizhanovsky and Lowe, 2009). Furthermore, a Gli1 and Trp53 
negative regulatory loop was described to control NSC numbers (Stecca and Ruiz i Altaba, 
2009), whereby Gli1 negatively regulates Trp53 to increase stem cell activity and Trp53 in turn 
inhibits Gli1 activity, thereby ensuring the control of NSC proliferation. However, in the 
Ptch1
LacZ/+
;Trp53
-/- 
genotype, it can be hypothesized that both genetic mutations alter the stem 
cell activity, as the Ptch1 mutation will lead to an increase in downstream Gli1 expression and 
the Trp53 null genotype to a deregulation in the inhibitory loop. The activation of the HH-GLI 
pathway has been reported to maintain the self-renewal of glioma stem cells (Clement et al., 
2007) and induce an ES stem-like signature in metastatic colon cancers (Varnat et al., 2010). 
Furthermore, Gli2 has been reported to bind to the enhancer and activate the transcription of 
Sox2 in neuroepithelial cells (Takanaga et al., 2009), providing a potential mechanism for the 
increased Sox2 expression in a Ptch1
LacZ/+
;Trp53
-/-  
mutants. Stat3 signaling also converges onto 
Sox2, as the direct regulation of Sox2 by Stat3 has been described in neural precursor cells 
(Foshay and Gallicano, 2008). Furthermore, the upregulation of both Gli and Sox2 transcription 
factors in the Ptch1
LacZ/+
;Trp53
-/-  
mutant background may lead to an increased co-binding of 
Gli1 and Sox2 to activate the expression of cooperatively regulated target genes, as observed 
during neural patterning and progenitor specification (Peterson et al., 2012). Transcriptional 
profiling of the CbSC and aberrant tissue stem cells will allow for us to determine if a gene 
signature specific for CbSC can be identified and if enhanced activation of a subset of genes in 
the aberrant tissue stem cell are coregulated by Gli and Sox2. 
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Figure 4-1 Tentative hypothesis for the aberrant persistence of Sox2-expressing cerebellar stem cell in the 3 
week Ptch1
LacZ/+
;Trp53
-/- 
animals 
In the WT CbSC, the Gli1-p53 negative regulatory loop regulating stem cell numbers is intact and CbSC genes are 
expressed at normal levels. However, in the Ptch1
LacZ/+
;Trp53
-/- 
cerebella, loss of p53 and Ptch1 inactivation may be 
leading to enhanced Gli1 activation, which in cooperation with Sox2 may be aberrantly maintaining a subset of 
CbSC genes. Furthermore, high levels of Stat3 expression, which is observed in MBNS, may also be playing a role 
in maintaining the persistent expression of its target gene Sox2. 
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